Author: Editor

Audio Only: Audio, Video and Slides What’s New in Oncology? – Key Updates from Recent Research Welcome to the latest edition of What’s New in Oncology?, your go-to source for the most current insights in cancer research. This week, we’re diving into groundbreaking studies from the Journal of Clinical Oncology and other leading publications, covering metastatic prostate cancer, breast cancer, lung metastasis, and neuroblastoma. Here’s a detailed breakdown of the latest findings that are shaping the future of oncology. KEYNOTE-921 Trial: Immunotherapy in Metastatic Castration-Resistant Prostate Cancer (MCRPC) A new article from the Journal of Clinical Oncology explores the KEYNOTE-921…

Date: March 11, 2025 Renowned Cancer Researcher Honored in 2025 The American Association for Cancer Research (AACR) and the Pezcoller Foundation proudly announce that Douglas Hanahan, PhD, FAACR, has been awarded the 2025 Pezcoller Foundation-AACR International Award for Extraordinary Achievement in Cancer Research. Hanahan, a Ludwig Distinguished Scholar at the Ludwig Institute for Cancer Research in Lausanne, Switzerland, will be celebrated at the AACR Annual Meeting 2025, held April 25-30 in Chicago. Groundbreaking Contributions to Cancer Science Hanahan’s pioneering work has reshaped cancer research. He co-authored the “Hallmarks of Cancer” with Robert Weinberg, PhD, providing a vital framework for understanding…

LOS ANGELES AACR IO 2025 At a recent oncology session from AACR Immunotherapy 2025, Melissa G. Lechner, MD, PhD, presented findings on the challenges of cancer immunotherapy. She focused on its autoimmune side effects and a newly identified link to bone health. The discussion highlighted the therapy’s expanding role and the need to address its risks as it reaches more patients. The Growing Challenge of Immunotherapy Side Effects Dr. Lechner began by framing the issue: “We had today was talking about immunotherapy and the autoimmune side effects that it can cause unhealthy tissues.” She noted that these effects are common,…

March 4, 2025 New Treatment Option for ESCC Patients The U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr) in combination with platinum-containing chemotherapy. This approval is for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1%). The approval, announced on March 4, 2025, offers a new treatment option for this patient group. Dr. Nataliya Uboha, Associate Professor at the University of Wisconsin Carbone Cancer Center, noted, “The approval of TEVIMBRA in combination with chemotherapy for adult patients with ESCC expands first-line treatment options for patients with this disease.…

Katy Beckermann, MD, PhD – Vanderbilt University The phase 3 TiNivo-2 study (NCT04987203), sponsored by AVEO Pharmaceuticals, Inc., recently evaluated tivozanib (TIVO) combined with nivolumab (NIVO) versus TIVO monotherapy in patients with renal cell carcinoma (RCC) who progressed after immune checkpoint inhibitor (ICI) therapy. While the study didn’t meet its primary endpoint of improved progression-free survival (PFS) with the combination, it offers valuable insights into patient-reported outcomes (PROs) and treatment implications. Study Design and Key Findings Patients received either TIVO 0.89 mg + NIVO or TIVO 1.34 mg alone as second-line (2L) or third-line (3L) therapy. PFS results showed:…

A Novel Tyrosine Kinase Inhibitor Poised to Transform Advanced Lung Cancer Care Boehringer Ingelheim | Ridgefield, Conn., and Ingelheim, Germany | February 19, 2025 On February 19, 2025, Boehringer Ingelheim announced that the U.S. FDA has granted Priority Review to zongertinib (BI 1810631), an investigational oral tyrosine kinase inhibitor (TKI) targeting HER2 (ERBB2) mutations in non-small cell lung cancer (NSCLC). This milestone underscores the urgent need for targeted therapies in this molecularly defined subset of lung cancer patients. Indication: Adult patients with unresectable or metastatic NSCLC harboring HER2 (ERBB2) mutations, who have progressed on prior systemic therapy. Mechanism: Zongertinib selectively…

Original Authors:  Luís F Leite da Silva, Erick F Saldanha, Júnior Samuel Alonso de Menezes, Leonardo Halamy Pereira, João Alexandre R de Bragança Dos Santos, Isabella Romagnoli Buonopane, Erito M de Souza, Caio Ulysses Galvani de Menezes, Gilberto Lopes PMID: 39998904 | PMCID: PMC11853598 | DOI: 10.1093/oncolo/oyae344 | Date: March 03, 2025 Abstract Background: Predicting early treatment response in advanced non-small cell lung cancer (NSCLC) is challenging. Longitudinal monitoring of circulating tumor DNA (ctDNA) can track tumor response to treatments like immune checkpoint blockade (ICB) and correlate with outcomes. This meta-analysis evaluated whether ctDNA clearance or decrease is associated with…

Posted on February 28, 2025 | Jose Ramon Conejo-Garcia,MD, PHD – Duke Cancer Institute Cancer immunotherapy has long been dominated by T cells and immune checkpoint inhibitors. However, a groundbreaking presentation by Jose Ramon Conejo-Garcia, MD, PhD, from Duke Cancer Institute, is shifting the spotlight to an overlooked player: humoral immunity. In a recent talk, Dr. Conejo-Garcia shared how isotype-switched antibodies produced in tertiary lymphoid structures (TLS) could hold the key to antagonizing human cancer progression. This offers new hope for more effective treatments. Here’s what you need to know about this exciting frontier in cancer research. The Power of…

February 26, 2025 | By Michael Karin, Phd Liver cancer, specifically hepatocellular carcinoma (HCC), is on the rise—and a sneaky culprit called Metabolic-Associated Steatohepatitis (MASH) is driving the surge. This inflammatory liver condition, tied to our modern diets, is sparking a scientific revolution. Fresh research from 2025 unveils how fructose-heavy meals, DNA damage, and rogue immune cells are conspiring against us—and how we might fight back with unexpected allies like a common blood pressure drug. Let’s dive into this game-changing science. MASH: The Silent Epidemic MASH is no small-fry health issue. Its incidence is climbing fast, especially in the US…

Los Angeles, February 2025 The AACR IO 2025 conference in Los Angeles has become a beacon for cutting-edge cancer research. This year, Kari L. Kendra, MD, PhD from The Ohio State University delivered a transformative presentation on desmoplastic melanoma (DM). This rare subtype of melanoma is characterized by its presence in high sun-exposed areas with extensive UV damage and a high tumor mutational burden. It is emerging as a pivotal focus in immunotherapy innovation. Dr. Kendra’s insights, shared with a global audience of researchers and clinicians, highlight why DM is achieving unprecedented response rates. They also present what this means…

Los Angeles, February 2025 – The inaugural AACR IO Conference kicked off with an electrifying start, bringing together the world’s leading experts in immunotherapy for a groundbreaking event in downtown Los Angeles. This vibrant gathering showcased the best minds in the field. They delivered two unforgettable keynote sessions that set the stage for innovation in cancer research. Highlights from the Keynotes A Collaborative Hub for Immunotherapy AACR IO 2025 is designed to unite diverse backgrounds—spanning vaccines, immune response modeling, cytokines, cell therapies, and cell engineering. This interdisciplinary approach creates a dynamic and exciting platform for sharing ideas. It drives progress…

Could 2025 Oncology Have Saved Steve Jobs from Pancreatic Cancer? A Deep Dive into Past and Future Treatments February 21, 2025 | By OncologyTube Steve Jobs, the genius behind Apple, left an indelible mark on technology—but his battle with pancreatic neuroendocrine tumor (pNET) cut his journey short in 2011. Diagnosed in 2003, Jobs faced a rare form of pancreatic cancer with a better prognosis than most, yet his choices—delaying conventional treatment for alternative therapies—and the limited options of the time couldn’t stop the disease’s progression. But what if Jobs had been diagnosed today, with access to 2025’s cutting-edge oncology? Could…

MRI’s Role in Prostate Cancer Diagnosis – A 3-Year Study Breakthrough Date: February 20, 2025 Prostate cancer, the second most common cancer in men globally, has long relied on PSA tests and digital rectal exams (DRE), often leading to invasive biopsies. But what if an MRI could safely spare men from this procedure? A groundbreaking 3-year cohort study published in JAMA Oncology (December 12, 2024) offers compelling evidence that it can. Led by Dr. Charlie A. Hamm at Charité–Universitätsmedizin Berlin, this research redefines prostate cancer diagnosis with prebiopsy multiparametric MRI (mpMRI). Here’s what you need to know. The Study at…

FDA Approves Enhertu for HR-Positive, HER2-Low and HER2-Ultralow Breast Cancer: A New Milestone in Treatment Published: February 20, 2025 On January 27, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki—better known as Enhertu—for patients with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow breast cancer. This approval marks a significant step forward, offering new hope to those whose cancer has progressed after endocrine therapy. Developed by Daiichi Sankyo, Inc., Enhertu is the first therapy specifically approved for HER2-ultralow breast cancer, expanding treatment options for a previously underserved group. Who Does Enhertu Help? Enhertu targets adults with hormone receptor-positive…

On February 14, 2025, the U.S. Food and Drug Administration (FDA) delivered a Valentine’s Day gift to patients battling symptomatic tenosynovial giant cell tumor (TGCT): the approval of vimseltinib (Romvimza), a novel kinase inhibitor developed by Deciphera Pharmaceuticals, LLC. This marks a significant milestone for adults with TGCT—a rare tumor affecting joints and tendons—especially in cases where surgery could worsen function or cause severe morbidity. What is TGCT, and Why Does This Matter? Tenosynovial giant cell tumor is an uncommon condition that can lead to pain, swelling, and restricted movement. For many patients, surgical removal is the go-to treatment, but…

Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of Londonon February 17, 2025 At the 2025 ASCO Genitourinary Cancers Symposium, the latest findings from the EV-302 study were presented, providing an updated analysis on the efficacy of combining enfortumab vedotin with pembrolizumab (EV+P) versus standard chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). Key Points from the Enfortumab Vedotin EV-302 study: Dr. Thomas Powles, MBBS, MRCP, MD, from Barts Cancer Institute at Queen Mary University of London, highlighted the importance of these findings, stating, “Enfortumab vedotin is the first…

Extended CheckMate-274 Results Show Continued Benefit With Nivolumab in MIBC Date: February 14, 2025 Author: Dr. Matthew I. Milowsky, MD, FASCO, University of North Carolina School of Medicine Key Points: Quotes: Continued DFS Benefit: The CheckMate-274 trial, a phase 3 study, had previously established a significant DFS benefit with adjuvant nivolumab: Promising OS Trend: PD-L1 Expression and OS: Safety Profile: Future Directions: Conclusion: Dr. Milowsky concluded, “The fact that the study continues to demonstrate significant improvement in disease-free survival, and that this interim overall survival data looks very promising, is very exciting.” Note: This post aims to consolidate and present…

Transforming MIBC Treatment: Insights from the NIAGARA Trial Posted on February 16, 2025 The landscape of treating muscle-invasive bladder cancer (MIBC) has potentially shifted with the latest insights from the phase III NIAGARA trial. Here’s a concise overview of what you need to know: Understanding MIBC: NIAGARA Trial Highlights: Clinical Implications: Conclusion & Future Directions: Durvalumab has shown promising results in enhancing survival outcomes for MIBC. However, future studies need to consider comparisons with potentially outdated chemotherapy regimens. The path forward includes integrating these findings into clinical practice and refining the treatment approach for even better patient outcomes. Stay tuned…

Talazoparib + Enzalutamide Introduction: We are excited to share the latest findings from the TALAPRO-2 Trial, which marks a significant advancement in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Here’s a deep dive into what this means for patients and the medical community. TALAPRO-2 Study Overview: The TALAPRO-2 study is a Phase 3 clinical trial that has set out to evaluate the efficacy of combining Talazoparib with Enzalutamide compared to Enzalutamide alone for patients newly diagnosed with mCRPC. This study aims to set new standards in first-line treatment approaches. Background on mCRPC Treatment: mCRPC represents a challenging stage of…

Date: February 12, 2025 FDA Approves Adcetris Overview The FDA has approved a new combination therapy for adults with relapsed or refractory Large B-cell Lymphoma (LBCL) on February 11, 2025. This therapy combines Brentuximab Vedotin (Adcetris), Lenalidomide, and Rituximab and is intended for patients who have undergone at least two prior systemic therapies and are not eligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy. Key Details of the Approval: This approval provides an additional treatment option for LBCL patients. For more detailed information, the full prescribing guide will be available on Drugs@FDA. Clinical Practice Implications: This…

FDA Approves Mirdametinib for NF1-PN: A New Option for Patients Introduction: The FDA has recently approved Mirdametinib (Gomekli) from SpringWorks Therapeutics for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) in patients aged 2 years and older. This approval is based on the outcomes of the phase 2b ReNeu clinical trial. The approval offers new hope and options for managing this condition. Below is a detailed look at the drug’s approval, trial results, and implications. The Approval: Efficacy: Treatment Regimen: Eligibility and Safety: Key Takeaways: Looking Forward: Conclusion: The FDA’s approval of Mirdametinib marks an addition to therapeutic options…

MOASC: Medical Oncology Association of Southern California Welcome to MOASC’s Digital Presence on OncologyTube The Medical Oncology Association of Southern California (MOASC), established in 1990, is dedicated to advancing and protecting the ability of cancer patients to receive optimal care, while empowering oncology physicians to provide it. Representing over 600 hematologists/oncologists across Southern California, from community practices to academic centers like UC Irvine, UC San Diego, and the University of Southern California, MOASC serves as a pivotal resource for its members. Our Vision MOASC’s vision is clear: to ensure continued access to top-tier cancer care. Through our YouTube channel on…

Date: February 8, 2025 The U.S. Food and Drug Administration (FDA) has recently granted approval for datopotamab deruxtecan (DLNK), a new treatment option for adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This marks a significant advancement in the fight against breast cancer, particularly for those who have progressed after prior endocrine-based therapies. Key Points: This approval provides hope and an additional therapeutic avenue for patients facing advanced stages of this type of breast cancer, potentially improving outcomes where previous treatments have failed. For more detailed information, including clinical trial data,…

Dive into the groundbreaking results of the EMBER-3 Phase 3 trial (NCT04975308) as presented by Dr. Virginia Kaklamani from UT Health San Antonio at the San Antonio Breast Cancer Symposium (SABCS). This trial focuses on imlunestrant, an innovative oral Selective Estrogen Receptor Degrader (SERD) specifically designed for patients with ER+, HER2- Advanced Breast Cancer (ABC) who have already been treated with endocrine therapy. Key Findings from the EMBER-3 Trial: What Does This Mean for Patients? Watch our video for an in-depth discussion on these findings, what they could mean for the future of breast cancer treatment, and how they might…

Overview: The results from the Phase 3 CheckMate-8HW trial have just been released, demonstrating significant improvements in outcomes for patients with metastatic colorectal cancer (mCRC) exhibiting high-level microsatellite instability or deficient mismatch repair (MSI-H/dMMR). This study marks the first direct comparison between dual and single-agent immunotherapy in this patient population. Key Findings: Study Details: Implications for Practice: Next Steps: Download Slides Here: Hashtags: #CheckMate8HW #Nivolumab #Ipilimumab #MSIH #dMMR #ColorectalCancer #mCRC #CancerResearch #Oncology #Immunotherapy #ClinicalTrials Note: This post is for informational purposes and should not replace consultation with healthcare professionals for treatment decisions. Related Articles: https://dailynews.ascopubs.org/do/checkmate-8hw-nivolumab-ipilimumab-demonstrates-improved-outcomes-over-standard

Abstract: Circulating tumor DNA (ctDNA) has a short half-life (<2 hours) which may permit real-time monitoring of tumor status. This single-institution study aimed to assess the feasibility of rapid treatment response evaluation through serial short-interval ctDNA testing. Patients with gastrointestinal (GI) cancer undergoing immune checkpoint inhibitor (ICI)-based therapy were included. A personalized, tumor-informed ctDNA assay (Signatera, Natera, Inc.) was used to measure changes in ctDNA levels between the first cycle (C1D1) and the second cycle (C2D1). The study found a strong correlation between ctDNA kinetics and treatment response in 86% of cases. This suggests that this method could guide treatment…

In the evolving landscape of cancer care In the evolving landscape of cancer care, the use of circulating tumor DNA (ctDNA), also known as liquid biopsies, is becoming increasingly significant in the management of colorectal cancer. This is true regardless of the stage at diagnosis. Recent discussions and studies have shed light on how ctDNA can guide treatment decisions, particularly in patients with stage II and III colorectal cancer. For stage II colorectal cancer patients, the decision to administer adjuvant chemotherapy is nuanced and complex. It involves a detailed review of the pathology report and multiple risk factors. It’s important…

BRCA Carriers Slicing Breast Cancer Odds: Does Surgery Really Lead to Longevity Leaps? Text: @OncoAlert @oncology @BreastCancerNow @SABCS @ProfMatteoLambertini #SABCS24 #BRCA #CancerPrevention #BreastCancerSurvival #RiskReducingSurgery #OncologyResearch #BRCAmutation… pic.twitter.com/2XZofthBCC— Oncology Tube (@oncologytube) December 17, 2024 Introduction: Prof. Matteo Lambertini presented the findings from the international BRCA BCUI collaboration study during SABCS 2024. The study focuses on the impact of risk-reducing surgeries in young BRCA mutation carriers with a history of breast cancer. “The risk of relapse of the primary breast cancer should be balanced with the risk of developing a second primary malignancy.” – Prof. Matteo Lambertini Background: BRCA gene mutations are…

Palbociclib (IBRANCE) Revs Up Metastatic Breast Cancer in PATINA Results Text Version: @DFCI_BreastOnc @Otto_DFCI @OncoAlert @PfizerIbrance @pfizer_news @SABCSSanAntonio @AACR #SABCS24 #Palbociclib #IBRANCE #PATINAStudy #MetastaticBreastCancer #ERHER2Positive #CDK46Inhibitors… pic.twitter.com/WkCCM22flL— Oncology Tube (@oncologytube) December 17, 2024 Update on the PATINA Phase 3 Study: Palbociclib in ER+/HER2+ Metastatic Breast Cancer Approximately 20% of breast cancers overexpress HER2, with 50% of these patients also expressing the estrogen receptor. While anti-HER2 therapies have improved survival outcomes, resistance remains a significant challenge. The rationale for using CDK4/6 inhibitors like palbociclib in HER2-positive disease stems from known benefits in ER-positive settings. The PATINA study, a phase 3 trial,…

We recognize that That combination also made them immunogenic. And so there was always recognition. Over time we came to appreciate that when you see the immune system in there where there’s immune lymphocytes in the tumor, those tumors, those patients seem to do better even in the absence of drug therapy and with drug therapy they do better still.

“So basically, we looked at two factors, the one saying the long term remission of heart positive metastatic breast cancer patients treated with trastuzumab based therapy. We specifically looked at some of those that had prolonged remission for more than five years.” – Dr. Aydah Al-Awadhi In an enlightening deep dive into the world of oncology, Dr. Aydah Al-Awadhi shares insights from a single-center retrospective analysis focused on the factors contributing to long-term remission in patients with HER2-Positive Metastatic Breast Cancer treated with Trastuzumab-based therapy. Study Overview: Clinical Implications: This study not only sheds light on the predictors of long-term…

In his analysis, Paolo Tarantino, MD, delves into the transformative potential of CDK4/6 inhibitors in breast cancer therapy. He questions whether these drugs, celebrated for their promise in clinical trials, have truly matched expectations in real-world scenarios, specifically referencing data from the NATALEE and monarchE trials. The discussion is visually represented by a superhero figure donning a CDK4/6 emblem, symbolizing the hope and power these inhibitors bring to the fight against breast cancer. This image captures the essence of current medical debates surrounding the efficacy and application of these treatments in managing breast cancer recurrence and overall patient outcomes.

The ZEST trial marks a pivotal moment in oncology, focusing on circulating tumor DNA (ctDNA) surveillance to detect molecular residual disease in breast cancer patients. This study explored whether Niraparib, a PARP inhibitor, could extend disease-free survival in patients with detectable ctDNA post-treatment but without visible signs of recurrence. The findings offer insights into both the potential and the limitations of using ctDNA for personalized cancer management.

The San Antonio Breast Cancer Symposium (SABCS) 2024 showcased new data from the DESTINY-Breast06 study, examining the efficacy of ENHERTU® (Trastuzumab Deruxtecan, T-DXd) versus physician’s choice of chemotherapy in hormone receptor-positive metastatic breast cancer patients. Study Overview: Dr. Aditya Bardia presented the findings from DESTINY-Breast06, a Phase 3 trial that included patients with HER2-low and HER2-ultra-low metastatic breast cancer who progressed rapidly on prior first-line endocrine therapy. Patients were randomized to receive either ENHERTU® or standard chemotherapy options. Key Findings: Safety Profile: Quality of Life: The study indicated that ENHERTU® could potentially enhance quality of life by controlling disease progression,…

EMBER-3 Trial: Pioneering Results in Advanced Breast Cancer Treatment The results of the Phase 3 EMBER-3 trial were unveiled at the SABCS 2024 conference, presenting critical insights into advanced breast cancer treatment. This global, open-label trial investigated the efficacy and safety of Imlunestrant, an oral endocrine therapy, for ER-positive, HER2-negative advanced breast cancer patients. Key Trial Overview: The study included 874 participants who were divided into three treatment arms: The trial assessed progression-free survival (PFS) as the primary endpoint, alongside secondary and exploratory outcomes such as overall survival and biomarker analysis. Results Summary: Safety and Tolerability: Implications: The trial underscores…

Overview of the CONFORM™ Platform The CONFORM™ platform by EDETEK offers a multifaceted approach to managing clinical data, focusing on five core areas: Oncology-Focused Accelerator: CONFORM™ – ONCO+ For oncology, which presents unique challenges due to its data complexity, EDETEK introduced CONFORM™ – ONCO+. This accelerator: Broader Application and Adoption While CONFORM™ – ONCO+ is focused on oncology, the CONFORM™ platform supports a wide array of therapeutic areas, including CNS, rare diseases, and cardiovascular, and is trusted by half of the top pharmaceutical companies and numerous smaller to mid-size entities. This wide adoption underscores its versatility and impact across the…

The GALAXY Study has provided compelling data that highlights the predictive value of circulating tumor DNA (ctDNA) status in colorectal cancer outcomes. Using Natera’s Signatera test, this study offers oncologists key insights into how ctDNA can be used to monitor disease recurrence, guide therapy decisions, and potentially redefine patient management strategies. Study Design and Participants This large-scale study involved 2,240 patients with stage 2 to stage 4 colorectal cancer (CRC). The median follow-up period was 23 months, and the study focused on the predictive role of ctDNA status in assessing disease-free survival (DFS) and overall survival (OS). The Signatera test,…

The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic malignant pleural mesothelioma (download slides below). This marks the first new treatment for mesothelioma in over 15 years, providing a new option for patients battling this aggressive disease. Key Results from the KEYNOTE-483 Trial The approval was based on findings from the KEYNOTE-483 trial, a randomized, open-label, phase 3 study involving patients with unresectable, advanced, or metastatic malignant pleural mesothelioma who had not received prior systemic therapy. Participants were randomized to receive either pembrolizumab with pemetrexed and platinum-based chemotherapy for…

The FDA has recently approved Kisqali (ribociclib) in combination with a non-steroidal aromatase inhibitor (NSAI) for the treatment of early-stage HR+/HER2- breast cancer in patients at high risk of recurrence (download slides below). This approval provides a new treatment option for patients, aiming to reduce the likelihood of cancer recurrence during the early stages of the disease. Key Findings from the NATALEE Trial The NATALEE trial was a randomized, open-label, multicenter phase 3 trial that included 5,101 adults with HR-positive, HER2-negative early breast cancer. Patients were selected based on lymph node involvement or tumor size and grade, ensuring a diverse…

iTeos Therapeutics and GSK revealed promising results from their phase 2 TIGIT trial at the 2024 European Society for Medical Oncology (ESMO) conference in Barcelona. The mid-stage trial, known as GALAXIES Lung-201, evaluated the combination of belrestotug, an anti-TIGIT antibody, and dostarlimab (Jemperli), GSK’s anti-PD-1 treatment, in patients with previously untreated, unresectable, or metastatic PD-L1-high non-small cell lung cancer (NSCLC). The results demonstrated a 30% improvement in tumor shrinkage with the combination therapy compared to dostarlimab monotherapy. The overall response rate (ORR) was impressive across all dosing cohorts: These results stand in contrast to the 37.5% ORR for patients who…

On September 12, 2024, the U.S. Food and Drug Administration (FDA) approved Tecentriq Hybreza, the first subcutaneous (SC) formulation of a PD-(L)1 inhibitor for cancer treatment. Developed by Genentech, Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) allows for a 7-minute subcutaneous injection, significantly reducing the 30 to 60 minutes typically required for intravenous (IV) administration of Tecentriq. This new formulation provides an alternative treatment option for patients with cancers such as non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), and others. New Administration Option for Cancer Patients Tecentriq Hybreza is expected to offer patients and healthcare providers…

On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy for use as neoadjuvant treatment, followed by single-agent durvalumab as adjuvant therapy, in adults with resectable non-small cell lung cancer (NSCLC). This approval applies to patients with tumors measuring 4 cm or greater and/or node-positive disease, excluding those with known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. Key Findings from the AEGEAN Trial The approval was based on efficacy data from the AEGEAN trial (NCT03800134), a randomized, double-blind, placebo-controlled, multicenter trial involving 802 patients with…

AVEO Oncology, a subsidiary of LG Chem, has announced the acceptance of its Phase 3 TiNivo-2 trial for a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17. The oral presentation will provide key results from the TiNivo-2 clinical trial, which evaluated the efficacy and safety of combining nivolumab, a PD-1 checkpoint inhibitor, with FOTIVDA® (tivozanib), a VEGFR tyrosine kinase inhibitor (TKI). The study compared the effects of this combination to standard dose tivozanib monotherapy in patients with metastatic renal cell carcinoma (RCC) who had progressed after…

Dr. Nathalie M. Johnson, MD, a breast cancer specialist with Legacy Health Partners, delves into the evolving role of circulating tumor DNA (ctDNA) in the management of breast cancer. As the field of oncology continues to advance, Dr. Johnson emphasizes the importance of adopting ctDNA testing more widely to improve patient outcomes, particularly for those with high-risk breast cancer types. The Role of ctDNA in Breast Cancer Management Dr. Johnson begins by highlighting how ctDNA is becoming a crucial tool in her practice. Although there aren’t standardized guidelines for its use just yet, she stresses that ctDNA testing can be…

Introduction Dr. Kevin Hughes, MD, from MUSC Health, sheds light on a critical issue in the field of oncology: the underutilization of genetic testing among patients who could significantly benefit from it. Despite the availability of commercial genetic testing for the past 25 years, an astonishing 90% of patients with genetic mutations remain unaware of their status. This lack of awareness often leads to missed opportunities for early intervention and cancer prevention. The Problem with Current Genetic Testing Practices Dr. Hughes points out that many patients with mutations that could predispose them to cancer are diagnosed late because they were…

Introduction On August 2, 2024, the FDA granted accelerated approval to afamitresgene autoleucel (TECELRA) for treating adults with unresectable or metastatic synovial sarcoma. This approval marks a significant advancement in immunotherapy for synovial sarcoma, a rare and aggressive cancer type. TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy. This treatment is specifically for patients who have previously undergone chemotherapy and whose tumors express the MAGE-A4 antigen. Clinical Trial and Efficacy The approval was based on the results from the SPEARHEAD-1 trial, a multicenter, single-arm, open-label study. This trial included patients with inoperable or metastatic synovial…

On August 1, 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for dostarlimab-gxly (Jemperli), in combination with carboplatin and paclitaxel, for adult patients with primary advanced or recurrent endometrial cancer. This new approval allows the use of dostarlimab-gxly not only in mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) patients but also in the broader population of those with primary advanced or recurrent endometrial cancer. Clinical Trial Evidence The approval was based on the results of the RUBY trial (NCT03981796), a randomized, multicenter, double-blind, placebo-controlled study involving 494 patients. Participants were randomized to receive either dostarlimab-gxly…

Introduction ASCO 2024 Head & Neck Cancer developments brought forth several groundbreaking studies in the field of head and neck cancer, showcasing advancements that could potentially change clinical practices. Dr. Shlomo Koyfman, MD, highlighted three pivotal studies that stood out during the conference. These studies delve into proton therapy, biomarker trials, and the role of immunotherapy, offering new insights and potential changes in treatment approaches for head and neck cancer patients. 1. IMRT vs. IMPT Proton Therapy Study The much-anticipated IMRT (Intensity-Modulated Radiation Therapy) versus IMPT (Intensity-Modulated Proton Therapy) phase three study finally provided data after a decade of research.…

Genetic Testing Cancer In recent years, the field of oncology has witnessed significant advancements, particularly in the realm of genetic testing. One such advancement is the use of circulating tumor DNA (ctDNA) monitoring, which has the potential to revolutionize cancer treatment and management. Dr. Erica Giblin, MD, from Ascension Medical Group, shares her insights and experiences with ctDNA testing, highlighting its impact on the detection and treatment of breast cancer recurrences. The Role of ctDNA in Early Detection Dr. Giblin emphasizes the importance of ctDNA monitoring, noting that it has been integrated into her practice for over a year. This…

In the evolving landscape of cancer treatment, ctDNA (circulating tumor DNA) testing has emerged as a pivotal tool in managing advanced cancers. In this insightful post, Dr. Barry Rosen, MD, shares his experiences and perspectives on using ctDNA testing, specifically the Signatera test, to detect molecular residual disease. This post highlights the key points from his discussion and explores the potential impact of ctDNA testing on treatment decisions. Signatera Test and Its Implementation: Dr. Rosen recalls that the Signatera test received commercial approval approximately two and a half years ago. He swiftly incorporated it into his practice for patients with…

Introduction: In a comprehensive presentation, Dr. Jacob Sands, MD, a medical oncologist, delves into the treatment options for small cell lung cancer (SCLC). He primarily discusses the use of Lurbinectedin and Irinotecan, both standard regimens in SCLC management. This discussion covers their individual and combined usage, potential synergy, clinical trial data, and their place in the current treatment paradigm. Chapters: 0:00:00 – Introduction: Standard Regimens for Small Cell Lung Cancer 0:01:00 – Enrollment Criteria and Patient Characteristics ‘0:02:00 – Second Line Treatment Options 0:03:00 – Synergy in Combination Therapy 0:04:00 – Adverse Events and Toxicity Management 0:05:00 – Encouraging Results…

Author: Dr. Shubham Pant, MD – MD Anderson Overview: At the ASCO 2024 conference, Dr. Shubham Pant, MD – MD Anderson shared exciting updates from the Phase 2 trial of zanidatamab, a bispecific HER2 antibody, in patients with HER2-positive biliary tract cancer (BTC). This trial highlights the potential of zanidatamab to improve treatment outcomes for this challenging cancer type. Mechanism of Action: Zanidatamab targets two domains on the HER2 protein (ECD2 and ECD4), which enhances receptor internalization and HER2 downregulation. This dual targeting mechanism leads to a more effective antitumor response compared to traditional HER2-targeted therapies. Study Design: Key Findings:…

Author: Dr. Zandra Klippel, Global Product Head, Multiple Myeloma, Sanofi At the ASCO 2024 conference, Dr. Zandra Klippel the Global Product Head, Multiple Myeloma, Sanofi summarizes the promising Phase 3 results from the IMROZ study. This study evaluated the combination of Sarclisa (isatuximab) with VRd (bortezomib, lenalidomide, and dexamethasone) in patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for transplant. Key Findings: Future Research Directions: Ongoing research aims to optimize dosing, reduce side effects, and expand the use of Isa-VRd to other myeloma populations, including those eligible for transplant. Future trials will explore different dosing schedules and delivery…

Author: Dr. Alexis LeVee, City of Hope At the ASCO 2024 conference, Dr. Alexis LeVee from City of Hope presented a pivotal Phase 1b clinical trial that explores the combination of CDK4/6 inhibitors and PD-1 inhibitors with endocrine therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- mBC). This study investigates how these combinations can enhance anti-tumor responses and improve clinical outcomes. Study Details: Results: Conclusion: The combination therapy shows promising results in enhancing immune response and improving clinical outcomes in HR+/HER2- mBC patients. Further evaluation in prospective trials is needed to confirm these findings. Abstract: A phase…

Author: Dr. Regina Barragan-Carillo, City of Hope Overview: At ASCO 2024, Dr. Regina Barragan-Carillo from City of Hope Cancer Center shared her pioneering research on how Latino ethnicity influences the gut microbiome composition in patients with metastatic renal cell carcinoma (mRCC). This study sheds light on the crucial link between ethnicity, gut microbiome, and treatment outcomes with immune checkpoint inhibitors. Study Highlights: Implications: This study emphasizes the importance of considering ethnic diversity in medical research and treatment strategies. Understanding the unique gut microbiome profiles of different ethnic groups can lead to more personalized and effective cancer treatments. Conclusion: Dr. Barragan-Carillo’s…

Presented by Dr. Hedyeh Ebrahimi, City of Hope Overview: At the ASCO 2024 conference, Dr. Hedyeh Ebrahimi of City of Hope presented an impactful study led by Dr. Alex Chehrazi Rafel. The study investigated the effectiveness of high-dose chemotherapy regimens in patients with recurrent germ cell tumors. This collaborative effort included contributions from four leading referral centers: City of Hope, UCSF, UC Davis, and UCLA. Study Details: Key Findings: Implications: The results highlight the potential benefits of the TICE regimen for improving overall survival in patients with recurrent germ cell tumors. Additionally, the identification of beta HCG as a prognostic…

… Dr. Sumanta (Monty) Kumar Pal, M.D., FASCO highlights some of the top data and presentations being presented in kidney and bladder cancer from ASCO 2024 annual meeting in Chicago. Below are 4 links to the data which was highligted: Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.https://meetings.asco.org/abstracts-presentations/231606 Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).https://meetings.asco.org/abstracts-presentations/231607 Biomarker…

Dr. Omid Hamid from The Angeles Clinic goes over his favorite presentations coming up at ASCO 2024. Should these be on your short list too? … Christian U. Blank – Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.https://meetings.asco.org/abstracts-presentations/234897 Jeffrey S. Weber – Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.https://meetings.asco.org/abstracts-presentations/233031 Sajeve Samuel Thomas – Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202…

What is Lorem Ipsum?Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.Why do we use it?It is a…

Introduction During a comprehensive presentation by Dr. Catherine Coombs at UC Irvine, insights into the unique challenges and opportunities of using CAR T-cell therapies in Chronic Lymphocytic Leukemia (CLL) were discussed. Despite CLL being a malignancy with numerous effective treatment options, CAR T-cell therapy has been relatively slow to gain approval. This detailed exploration highlights the potential and hurdles of integrating CAR T into CLL management, including a review of Lysacel and other significant treatments. The State of CAR T in CLL Challenges in CLL Dr. Coombs pointed out that CLL is characterized by immune dysfunction, which can impair the…

Introduction At a recent conference, Dr. Anjali Advani of the Cleveland Clinic discussed the transformative role of Chimeric Antigen Receptor T-cell (CAR-T) therapy in the treatment of acute lymphoblastic leukemia (ALL), especially in conjunction with bispecific antibodies and antibody-drug conjugates. Her talk offered a comprehensive overview of current therapies and explored the future of CAR-T in ALL treatment, providing crucial insights for oncologists. The Evolution of ALL Treatment Current Landscape Historically, adults with relapsed refractory ALL had dismal prognoses, but the landscape has shifted dramatically with the introduction of innovative therapies. Dr. Advani highlighted four pivotal agents currently approved for…

Introduction During the CAR-T & Bispecifics Conference, Dr. Brian Sworder, MD, from UCI Irvine, shared compelling insights on the utility of circulating tumor DNA (ctDNA) in the context of CAR-T cell therapy, particularly for relapsed refractory large B-cell lymphoma. This summary highlights the critical aspects of his presentation, emphasizing the revolutionary potential of ctDNA in predicting therapy outcomes and understanding resistance mechanisms. The Significance of Circulating Tumor DNA in Oncology Understanding ctDNA Circulating tumor DNA consists of small fragments of DNA shed by tumor cells into the bloodstream. It serves as a non-invasive biomarker that can be analyzed to detect…

Introduction During the recent CAR-T & Bispecifics conference, Dr. Nitin Jain, MD, from MD Anderson Cancer Center in Houston, Texas, presented a challenging case involving advanced B-cell lymphoblastic leukemia (BLL). This discussion offered profound insights into the nuanced decision-making processes in oncology, particularly in cases involving genetic complexities and multiple treatment failures. The session highlighted the evolving landscape of oncological treatment where genetic insights drive personalized medicine approaches. … Detailed Case Review and Genetic Implications Patient Background The focus was on a 25-year-old Hispanic male patient initially diagnosed with BLL in 2016. This patient’s medical journey has been significantly complicated…

Introduction The recent findings from the DESTINY-Breast06 Phase III trial signify a potential shift in the treatment landscape for HR-positive, HER2-low metastatic breast cancer. This landmark study evaluates the efficacy of Enhertu (trastuzumab deruxtecan), a specifically engineered antibody drug conjugate, marking significant strides in targeted cancer therapy. These results demonstrate substantial improvements in progression-free survival (PFS) compared to standard chemotherapy, offering new hope for patients with limited treatment options. Trial Design and Methodology Overview DESTINY-Breast06 is a global, randomized, open-label, Phase III trial that compares the effectiveness and safety of Enhertu against the investigator’s choice of standard chemotherapy, which includes…

Introduction The US Food and Drug Administration (FDA) recently approved nogapendekin alfa inbakicept-pmln (Anktiva), used in conjunction with bacillus Calmette-Guérin (BCG), marking a significant advancement in the treatment of non–muscle-invasive bladder cancer (NMIBC) unresponsive to BCG alone. This groundbreaking approval addresses a substantial unmet need within the high-risk bladder cancer population, offering new hope for thousands of patients across the United States. Background and Rationale Bladder cancer ranks as the sixth most prevalent cancer in the United States, with approximately 81,000 new cases annually and 17,000 deaths. NMIBC represents about 70% of all bladder cancer cases and is typically managed…

… Gabriel Mannis, MD Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine provides an in-depth analysis of Notable Lab’s Predictive Precision Medicine Platform. Dr. Mannis discusses the pivotal role of PPMP in advancing the treatment of Acute Myeloid Leukemia (AML), focusing on how its rapid and personalized approach can significantly enhance patient outcomes by tailoring therapies to individual needs. For more information visit www.NotableLabs.com For More Information Visit Notable Lab’s Predictive Precision Medicine Platform

Dr. Charles Link recently discussed the innovative SYNC-T technology (Syncromune® Inc.) during a phase one trial targeting hormone-refractory prostate cancer—a particularly challenging patient group. This post delves into the key aspects and outcomes of this trial, highlighting its significance in the field of oncology. … SYNC-T Technology: A Novel Approach from Syncromune® Inc. SYNC-T technology is an advanced treatment method that integrates a personalized vaccine with a multi-component biologic to target the immune system at the site of the tumor. This process involves directly injecting the tumor site, freezing part of the tumor to release antigens, and simultaneously infusing a…

Introduction to Emerging Therapies in ALL Management … Dr. Elias Jabbour shared recent developments in the treatment of acute lymphoblastic leukemia (ALL) during a recent medical conference. His presentation focused on the evolving landscape of ALL therapy, particularly emphasizing the growing importance of targeted therapies including bispecific antibodies, antibody-drug conjugates (ADCs), and tyrosine kinase inhibitors (TKIs). The integration of these therapies is reshaping the standard treatment protocols, potentially reducing reliance on conventional chemotherapy and transplantation. The Role of Tyrosine Kinase Inhibitors (TKIs) A significant portion of the session was dedicated to discussing the effectiveness of TKIs. Dr. Jabbour outlined the…

… The field of oncology is continuously evolving, with research focusing on developing more effective and personalized treatment modalities. One such significant stride in this direction is the KRYSTAL-1 study, which explores the efficacy and safety of combining adagrasib (MRTX849) with cetuximab in treating patients with metastatic colorectal cancer (CRC) harboring the KRASG12C mutation. This article delves into the study’s findings, its implications for clinical practice, and future research directions. Overview of the KRYSTAL-1 Study The KRYSTAL-1 study is a multicenter, phase 1/2 clinical trial that investigates the combination of adagrasib, a KRASG12C inhibitor, and cetuximab, an EGFR inhibitor, in…

… Pancreatic cancer, notorious for its lethality and late-stage diagnosis, presents significant challenges in oncological treatment and patient survival. Dr. Ajay Goel’s recent research introduces a transformative approach to early cancer detection through a blood-based liquid biopsy, leveraging microRNAs and exosomes for unparalleled accuracy. This article delves into the study’s methodology, findings, and its profound implications for the future of oncology. Early Detection: A Paradigm Shift Dr. Goel’s study addresses a critical issue in pancreatic cancer treatment—the disease’s diagnosis at an advanced stage, rendering it inoperable and drastically reducing survival chances. The research aims to circumvent this through early detection,…

… Lung cancer remains the leading cause of cancer-related deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. The discovery of specific mutations within NSCLC, such as those in the KRAS gene, has paved the way for targeted therapies. However, tumors harboring KRAS mutations, especially those with concurrent STK11 and KEAP1 mutations, have shown a worse prognosis due to their resistance to current therapies, including chemotherapy and immunotherapy. The work of Triparna Sen, PhD, sheds light on a novel therapeutic target, Stearoyl-CoA Desaturase 1 (SCD1), which plays a pivotal role in the metabolic rewiring of…

… Multiple myeloma, an incurable cancer affecting plasma cells in the bone marrow, continues to challenge the medical community. The search for more effective treatments has led to the development of innovative therapies targeting specific mechanisms involved in cancer progression. A significant breakthrough in this quest is Linvoseltamab, a BCMA CD3 bispecific antibody, which has shown promising results in relapsed and refractory multiple myeloma patients. Sundar Jagannath, MD, presented compelling data at the AACR, highlighting the efficacy and safety of this fully human antibody, which marks a potential paradigm shift in the treatment approach to multiple myeloma. Efficacy of Linvoseltamab…

… Introduction Small cell lung cancer (SCLC) is notoriously aggressive and challenging to treat, with current therapies often providing limited benefit due to the cancer’s rapid progression and recurrence. The search for more effective treatments has led to the exploration of combining traditional chemotherapies with immunotherapies to harness the body’s immune response against tumor cells. A promising development in this field is the use of Lurbinectedin, a therapy initially approved for second-line treatment of SCLC, which has shown potential in not only directly combating tumor cells but also in enhancing the efficacy of immunotherapy agents. The Mechanism of Lurbinectedin Lurbinectedin…

… The Medical Oncology Association of Southern California (MOASC) 2024 Summit has once again set a benchmark in oncology, providing a platform for groundbreaking research, discussions, and recognition of young talent in the field. Dr. Sumanta Kumar Pal, MD known as Monty, took a moment to reflect on the successes of this year’s summit, marking significant milestones and achievements that pave the way for future advancements in cancer research and treatment. Launch of the Young Investigator Award A highlight of MOASC 2024 was the inauguration of the Young Investigator Award, a commendable initiative sponsored by Aveo, aimed at acknowledging and…

The MOASC represents a prestigious accolade designed to recognize and encourage promising young researchers in the field of oncology. This award seeks to highlight individuals who have demonstrated exceptional potential through their innovative research, contributions to oncology, and commitment to advancing cancer care. Awardees are selected based on the novelty, impact, and scientific merit of their work, showcasing groundbreaking findings that could lead to significant advancements in the diagnosis, treatment, and understanding of cancer. The recognition not only celebrates the achievements of these emerging leaders in oncology but also aims to foster their career development, providing support and visibility within…

… At the MOASC Annual Oncology Summit & Research Symposium, Dr. Karen Reckamp, MD, MS, a leading figure in medical oncology at Cedars-Sinai, Los Angeles, CA, provided a comprehensive update on the transformative approaches in the perioperative management of non-small cell lung cancer (NSCLC). With a distinguished career marked by contributions to advancing treatment modalities, Dr. Reckamp’s insights into the integration of immunotherapy and targeted therapy in NSCLC offer valuable perspectives for oncologists navigating this evolving landscape. Oncogenic Drivers and Treatment Evolution in NSCLC The journey of NSCLC treatment has been significantly influenced by the understanding of oncogenic drivers and…

… Melanoma treatment has significantly evolved due to extensive research and the introduction of novel therapeutic options. Dr. Justin T. Moyers from The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, presented a detailed update on March 6, 2024, providing oncologists with the latest data and clinical insights into melanoma management. Key Studies and Approved Treatment Combinations CHECKMATE-067: Establishing a New Standard CHECKMATE-067 compared the effectiveness of nivolumab alone, nivolumab plus ipilimumab, and ipilimumab alone in patients with unresectable stage III or IV melanoma. This trial identified the combination of nivolumab and ipilimumab as superior in terms of progression-free survival…

… The field of oncology is witnessing a paradigm shift in the treatment of lymphomas, fueled by the emergence of groundbreaking studies and novel therapeutic agents. This detailed review, drawing from a presentation by Elizabeth Brem, MD, at the University of California, Irvine, delves into the significant strides made in Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) treatment. It examines pivotal trials, compares therapeutic strategies, and discusses their implications for current clinical practice, offering oncologists a roadmap for integrating these innovations into patient care. Hodgkin Lymphoma: Evolving Standards and New Horizons Revisiting ECHELON-1: A Benchmark in HL Treatment…

… Introduction to ADCs in Cancer Therapy The advent of targeted therapies has revolutionized the field of oncology, offering new hope and improved outcomes for patients with hematological malignancies. Among these innovative treatments, Antibody-Drug Conjugates (ADCs) such as Inotuzumab Ozogamicin (INO) and Gemtuzumab Ozogamicin (GO) have emerged as significant advancements. These therapies uniquely combine the specificity of monoclonal antibodies with the potent cytotoxicity of chemotherapeutic agents, specifically targeting cancer cells while sparing healthy tissue. However, the clinical application of INO and GO has unveiled a challenging aspect of their use: liver toxicity, including sinusoidal obstruction syndrome (SOS) and thrombocytopenia. Drawing…

… In the rapidly evolving field of oncology, colorectal cancer (CRC) represents a significant area of research and clinical development. Innovations in genetic profiling and targeted therapies have led to considerable advancements in the treatment of CRC, offering new hope and improved outcomes for patients. This article, grounded in the comprehensive data presented by Heinz-Josef Lenz, MD, from the USC Center for Cancer Drug Development at the 2024 MOASC Annual Oncology Summit & Research Symposium in Newport Beach California, aims to provide oncologists with an in-depth overview of the current state and future directions in CRC treatment. [EXCLUSIVE VIDEO with…

… [VIDEO & SLIDES] Alex Chehrazi –Raffle, MD, City of Hope – 2024 MOASC Annual Oncology Summit & Research Symposium In the ever-evolving field of oncology, the management of non-metastatic prostate cancer represents a significant area of interest due to the potential for curative treatment outcomes. With advancements in diagnostic techniques and treatment modalities, the approach to treating non-metastatic prostate cancer is becoming increasingly sophisticated. This article builds upon the insights provided by Alex Chehrazi-Raffle, MD, from the City of Hope Comprehensive Cancer Center, to explore the nuanced strategies in the systemic treatment of non-metastatic prostate cancer. It covers the…

… [VIDEO with 39 SLIDES] – Dr. Rebecca Shatsky, MD from the 2024 MOASC Annual Oncology Summit & Research Symposium In the rapidly advancing field of breast cancer treatment, the emphasis on personalizing therapy to individual patient needs and tumor characteristics has become increasingly paramount. Dr. Rebecca Shatsky, MD an esteemed Associate Professor of Clinical Medicine at UC San Diego, provides an in-depth exploration of the latest strategies and breakthroughs in breast cancer management at the 2024 MOASC Annual Oncology Summit & Research Symposium. This article delves into the critical aspects of her presentation, which spans the gamut from the…

Overview The U.S. Food and Drug Administration (FDA) has granted approval for the use of inotuzumab ozogamicin (Besponsa, Pfizer) in pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL). This decision represents a significant advancement in the treatment options available for this particular patient population. [Exclusive Video] Efficacy and Safety of Inotuzumab Ozogamicin (BESPONSA) – Mojtaba Akhtari, MD, FACP-Professor of Medicine-Loma Linda University – MOASC 2024 Advances in Oncology … Efficacy Evaluation The approval was based on data from a multicenter, single-arm, open-label study involving 53 pediatric patients aged 1 year…

On March 7, 2024, the Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib, marketed as Brukinsa by BeiGene USA, Inc., for the treatment of relapsed or refractory follicular lymphoma (FL) following two or more lines of systemic therapy. Study Background: ROSEWOOD Trial (BGB-3111-212) The approval was based on findings from Study BGB-3111-212, also known as the ROSEWOOD trial (NCT03332017). This open-label, multicenter, randomized trial enrolled 217 adult patients with relapsed or refractory FL after at least two prior systemic treatments. Patients were randomized in a 2:1 ratio to receive either zanubrutinib 160 mg orally twice daily in combination…

The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific antibody is being evaluated for its efficacy in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of therapy. The Importance of Priority Review Priority Review is granted by the FDA to investigational therapies that have the potential to significantly improve the safety or effectiveness of treating serious conditions compared to standard applications. This designation shortens the review period to six months, as opposed to the standard 10 months. If approved, epcoritamab-bysp (EPKINLY®)…

Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set of challenges for both patients and healthcare providers. Angela Fleischman, MD at Spotlight on Myelofibrosis 2024 from MOASC, focuses on the critical role of Janus kinase (JAK) inhibitors in managing this disease. Despite the common association of JAK2 V617F mutations with myeloproliferative disorders, Fleischman underscores the effectiveness of JAK inhibitors across various genetic mutations, expanding the therapeutic horizon beyond JAK-mutated patients alone. [VIDEO] 2024 Myeloproliferative Neoplasms Updates [33 SLIDES] – Angela Fleischman, MD, PhD – Spotlight on Hematology 2024 MOASC … Clinical Challenges of Myelofibrosis…

Zahra Pakbaz, MD, shed light on a range of critical findings from the American Society of Hematology (ASH) meeting, with a particular focus on the dynamic sphere of benign hematology. Amidst a potential shortfall in expertise within this field, Pakbaz’s research, conducted with a team of dedicated students, highlighted the pivotal role that hematologists play in the management of non-cancer blood disorders, such as sickle cell disease. This article delves into the significance of Non-Malignant Hematology Clinics, presenting Pakbaz’s insights on the vital presence of these clinics and the exciting potential that gene therapy holds for sickle cell disease and…

In 2024, CAR T-cell therapy continues to transform the landscape of treatment for hematologic malignancies, including multiple myeloma and various forms of lymphoma. Dr. Stefan Ciurea’s comprehensive discussion at a recent medical conference highlighted the significant strides made in this innovative treatment modality, underscoring its potential and challenges. This article delves into the updates, studies, and clinical experiences shared by Dr. Ciurea, offering a detailed view for physicians engaged in the field. [69 SLIDES with VIDEO] 2024 CAR-T-cell Hematology Updates – Stefan Ciurea, MD – MOASC … Advancements in CAR T-cell Therapy for Multiple Myeloma Recent trials have showcased the…

ASH Groundbreaking Trials and Therapies Transform Multiple Myeloma Treatment The recent American Society of Hematology (ASH) meeting showcased significant advancements in multiple myeloma treatment, with a particular focus on integrating CD38 monoclonal antibodies into frontline therapy and exploring the benefits of quadruplet regimens. These developments promise to reshape patient care, offering new hope for those battling this challenging disease and were highlighted at the MOASC Spotlight on Myeloma 2024. [VIDEO with 36 SLIDES] 2024 Multiple Myeloma Updates – Lisa X. Lee, MD … The Griffin and PERSIUS Trials: A New Era in Myeloma Treatment Dr. Lisa X. Lee highlighted the…

Assessing the Impact of COVID-19 on Cancer Screening and Diagnosis Rates in the United States: A 2020 Overview The COVID-19 pandemic, emerging from the discovery of the SARS-CoV-2 virus in 2019, has led to widespread disruptions across various sectors, including healthcare. Undiagnosed Cancer & COVID-19 is one of the less visible but highly impactful disruptions has been in the field of cancer screening and diagnosis. The pandemic’s interference with routine health care and cancer screening services has led to a significant drop in cancer diagnoses across the United States. This article delves into a comprehensive analysis conducted to understand the…

March 1, 2024 – In a significant advancement for lung cancer treatment, the Food and Drug Administration (FDA) has approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed. This new therapy is designated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as confirmed by an FDA-approved diagnostic test. Traditional Approval Granted for Amivantamab-vmjw The FDA has also issued traditional approval for amivantamab-vmjw for adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. This approval…

A New Horizon in Gene Editing In the rapidly evolving field of genetic medicine, a groundbreaking development has emerged with the introduction of a novel CRISPR-based tool, MEGA-CRISPR. This innovation promises to bring a significant transformation to cancer therapy, setting a new standard for precision medicine. Traditional CRISPR systems, known for their ability to edit DNA, have been pivotal in advancing genetic research and therapy. However, MEGA-CRISPR diverges from this path by targeting RNA instead, offering a more flexible and reversible method for modifying cellular behavior. This shift not only enhances the potential of cancer-fighting cells but also paves the…

The battle against polycythemia vera (PV), a rare and chronic form of blood cancer, has seen a transformative advancement with the introduction of rusfertide, a groundbreaking drug developed through the collaborative efforts of the Icahn School of Medicine at Mount Sinai. This innovative therapy has shown promising early success in clinical trials, heralding a potential paradigm shift in the management of PV, a condition that has historically been challenging to treat effectively. “Rusfertide appears to represent a significant step forward in treating polycythemia vera through its unique approach of limiting the amount of iron available for blood cell production,” states…

On February 15, 2024, the Food and Drug Administration (FDA) approved tepotinib, commercially known as Tepmetko®, for its use in adult patients with metastatic non-small cell lung (NSCLC) cancer exhibiting MET exon 14 skipping alterations. This milestone followed its previously granted accelerated approval, reflecting a substantial leap forward in precision medicine for lung cancer. Tepotinib’s Path from Accelerated to Traditional Approval Originally granted accelerated approval based on promising outcomes from the VISION trial, tepotinib’s journey to full FDA endorsement was underpinned by clinical scrutiny and an expanded dataset, affirming its role in targeting MET-dependent tumor cells in NSCLC. The European…

Teclistamab FDA approval biweekly dosing in Relapsed or Refractory Multiple Myeloma (3 KOL Video Interviews Below) On February 20th, 2024 the Teclistamab FDA approval of TECVAYLI® (teclistamab-cqyv) for biweekly dosing was announced as a significant advancement in the treatment landscape for relapsed or refractory multiple myeloma (RRMM), offering a new beacon of hope for patients battling this incurable blood cancer. This approval underscores the commitment to addressing the complex needs of patients with multiple myeloma, especially those who have shown resistance to previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Understanding Multiple…

What is the new treatment for metastatic melanoma? On February 16, 2024, the medical community witnessed a significant milestone in the fight against metastatic melanoma, a notoriously aggressive form of skin cancer responsible for a substantial number of cancer-related deaths worldwide. The Food and Drug Administration (FDA) granted accelerated approval to lifileucel (Amtagvi), marking the advent of the first cell therapy for adult patients with unresectable or metastatic melanoma that have exhibited resistance to conventional treatments. This novel T cell immunotherapy, developed by Iovance Biotherapeutics, Inc., is tailored for patients who have previously undergone treatment with a PD-1 blocking antibody…

On February 16, 2024, the Food and Drug Administration (FDA) announced the approval of osimertinib, marketed under the brand name Tagrisso by AstraZeneca Pharmaceuticals LP, in combination with platinum-based chemotherapy. This approval offers a new treatment avenue for adult patients battling locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by specific genetic mutations: EGFR exon 19 deletions or exon 21 L858R mutations. These mutations must be identified using an FDA-approved test, ensuring the targeted application of this therapy. The Clinical Landscape of NSCLC (Non small cell lung cancer) Non-small cell lung cancer represents a significant portion of lung…

We asked 5 top KOLS at ASCO GI 2024 the same questions on MRD and CTDNA testing. You might be surprised by the diverse answers. Investigating MRD and ctDNA Testing: Insights from Top KOLs at ASCO GI 2024 Introduction The landscape of oncology research is continually shaped by advancements in minimal residual disease (MRD) and ctDNAtesting (circulating tumor DNA), particularly in colorectal cancer. The American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) serves as a pivotal platform for sharing groundbreaking research and clinical insights among oncologists and researchers. We asked five top Key Opinion Leaders (KOLs) at ASCO GI…

… Anup Kasi, MD, Associate Professor and Vice Chair of GI Oncology at the University of Kansas Medical Center, is propelling forward the battle against metastatic pancreatic cancer, shedding light on the transformative potential of targeted therapies. Among these, KRAS G12C inhibitors and protein degraders have emerged as crucial weapons in targeting the KRAS gene mutations, which are pivotal in the oncogenesis of not only pancreatic cancer but also colorectal and lung cancers. This marks a significant shift towards precision medicine, focusing on the molecular underpinnings of cancer.KRAS Gene’s Role in OncologyThe KRAS gene, a member of the mammalian Ras…

Suneel Kamath, MD: [00:00:00] So this this trial that the tech 24 trial was really looking at a pan G. I. Population evaluating tucatinib plus trastuzumab and then full fax chemotherapy across a number of different G. I. Cancer. The thing that was really the strength of it is that this is recognizing really that her to amplification is extremely important biomarker. wE first found it in breast cancer, of course, and have been using gastric cancer and esophageal cancer for many years, but we’re starting to recognize more and more that this does really have kind of a tumor…

Van K. Morris, MD: [00:00:00] Thanks Allen for for having me and letting me represent our team of investigators who reported the results from the NRG-GI005 (COBRA) trial. This past weekend at the ASCO GI Symposium in San Francisco, this is a phase two trial that evaluated the role of circulating tumor DNA as a predictive biomarker for adjuvant chemotherapy in patients with low risk stage two eight colon cancer. This was also the first trial that the NCI ever supported evaluating circulating tumor DNA as an integral biomarker for any solid tumor type. So we all recognize that in…

Naureen Starling, MD: [00:00:00] Of course. So AZUR-2, as you said, is a global study. Open label, randomized, running in over 245 centers in over 26 countries globally. So a global study and patients. So 711 participants will be recruited with DMMR or MSI high. Resectable colon cancer stay with a clinical stage of T four N zero or stage three. And that’s by clinical staging. And participants will be randomized on a two to one basis between the experimental arm versus the control arm. And in the experimental arm, participants randomized to that arm will have neoadjuvant doss, which…

Sakti Chakrabarti, MD: [00:00:00] So Dream GI is a national database through which we collect data on localized GI cancer patients who have MSI high tumors and who have received immunotherapy up front. We also call it new adjuvant immunotherapy. The idea behind this database is that new adjuvant immunotherapy is being given to patients who have localized GI cancers and MSI high tumor, right now, outside of a clinical trial, because many of these patients are not good surgical candidates. If those patients are getting the treatment, it makes a lot of sense to collect that data and analyze…

Michael Weickert, PhD: [00:00:00] So the first thing I want to explain is Zelenirstat is a first in class therapy targeting a new target that’s never been drugged before for any indication. So this is the first time it’s been studied in patients and we do what’s called a phase one study which is primarily to identify safety. Is it safe to dose this new drug which has never been dosed before at a new target that’s never been drugged before? So our study was designed to escalate the dose gradually in a series of patients that are not selected…

Thejus Jayakrishnan, MD: [00:00:00] Those of you who have listened to the keynote address today by Dr. Ng from Dana Farber, she highlighted how there is an increasing incidence of early onset GI cancers. In fact, we’re seeing more and more young patients Young people developing cancers and the largest increase is happening in GI cancers and specifically in cholangiocarcinoma. So over the years we’ve seen more and more patients dying from cholangiocarcinoma and we do not know what is the reason for this and we also don’t know are there any features that are unique to young patients compared…

Sawyer Bawek, MD: So in colorectal cancer with liver metastasis, studies have shown that immunotherapy has a poor response on those patient populations. So what we wanted to do is one look at the role of immunotherapy and gastroesophageal cancer in patients with liver metastasis and see if it also has a poor response. So we looked at all phase three. randomized controlled trials looking at immunotherapy um, in advanced metastatic gastroesophageal cancer. And after analyzing all the studies, we found about seven studies that had data on overall survival and progress and free, progression free survival with liver metastasis.…

Anup Kasi, MD: [00:00:00] So this is an investigative initiated trial called the EPIC trial. Where we’re investigating n fotamibidotin, which is an antibody drug conjugate as a single arm, non randomized. Phase two study a single institution study at our site at University of Kansas in patients with advanced pancreatic cancer in the second line and beyond setting. As a phase two study, this primary objective of this study is looking at the objective response rate. And then we do have some secondary objectives such as OS, PFS, and safety analysis as well. OncologyTube: Given the aberrant overexpression of…

Simron Singh, MD: [00:00:00] So radioligand therapy is like in a new emerging treatment for cancer. where we try to inject radioactive isotopes through the body that bind to the cancer receptors and are taken up by the cancer cells and then the cancer cells are killed, but generally preserve healthy tissue. So the NETTER-2 clinical trial is the first clinical trial to date that examines this type of therapy as the first line therapy in any cancer. And so specifically with the NETTER-2 trial, we looked at advanced Grade two and grade three neuroendocrine cancers from the G. I. Tracked…

Howard S. Hochster, MD: [00:00:00] Um, first of all, this is for late line colorectal cancer after the standard chemotherapy and targeted therapy drugs. it’s a space where we’re seeing new drugs approved for colon cancer, but many people continue to have the need for additional treatments once they finish the approved drugs. this particular drug is quite novel, ME344. we are working, in the, AGIC group, the Academic GI Cancer Consortiwhich is an academically based Phase II national consortium. with MEI Pharma to test this drug. It’s novel because it interrupts mitochondr m my this is novel because it,…

OncologyTube: [00:00:00] Okay. We’re here at ASCO GI 2024. And, we have the honor of, having Dr. Christopher Lieu, MD medical doctor, associate director for clinical research, co director gastrointestinal medical oncology at University of Colorado and Aurora, Colorado. Dr. Lu, thank you so much for joining us. Well, thank you for having me. Okay, today we’ll be discussing the NRG-GI008 colon adjuvant chemotherapy based on evaluation of a residual disease otherwise known as the circulate North America trial, which is featured here at ASCO GI 2024. So Dr. Liu, can you provide an overview of the NRG G. I. …

OncologyTube: [00:00:00] Okay, here we are at ASCO GI 2024. We have Dominik Paul Modest, MD medical doctor from Charite,University of Medicine in Berlin. Dr. Modest, thank you so much for joining us today. You’re welcome. Today, we’ll be discussing health related quality of life in patients with metastatic colorectal cancer treated with sotorasib and panitumumab versus Trifluoridine, Tirapercel and regorafenib in Codebreak300, which is featured here at ASCO GI 2024. Dr. Matas, can you provide an overview of the Codebreak300 trial? Dominik Paul Modest, MD: Sure. Um, it’s a spectacular trial in a way because it’s three arm in…

OncologyTube: [00:00:00] Okay. Okay, we’re here at ASCO GI 2024 and we have Dr. Anthony B. El-Khoueiry, MD a medical doctor, associate professor of medicine at USC Norris Comprehensive Cancer Center, USC, in Los Angeles. Dr. El Khoury, thank you so much for joining us today. Pleasure. Okay. Today we’ll be discussing Tizolizumab plus chemotherapy with or without Bevacizumab and advanced biliary tract cancer results from a randomized proof of concept phase two trial, otherwise known as the IMBRAVE151, which has been featured here at ASCO GI 2024. So Dr. Okahiri, can you provide an overview of the IMBRAVE151 study…

OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Dr. Riccardo Lencioni, MD medical doctor, professor of radiology and director of cancer imaging program at the Pisa University School of Medicine in Italy. Dr. Lencioni, thank you so much for joining us. My pleasure. Today we’ll be discussing the Emerald 1, a phase 3 randomized placebo controlled study of tastes combined with Dorvalumab with or without Bevacizumab in patients with unresectable hepatocellular cancer. carcinoma eligible for embolization, which is featured here at ASCO GI 2024. Dr. Lencioni, can you provide the overview for the Emerald One…

OncologyTube: [00:00:00] We have Dr. Milind Javle, MD. He is from the Department of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. Thank you for joining Milind Javle, MD: us today. So I’m very excited to be here and discuss a phase 3 trial that has just been initiated in FGFR altered cholangiocarcinoma. To give you a background, FGFR altered cholangiocarcinoma can be treated now with Pemigatneb. Uh, and furibatinib. These are, uh, agents that are FDA approved. Unfortunately, resistance inevitably occurs, and this occurs after six to eight months, and after that,…

OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Jeanne Tie, MD a medical doctor, the medical oncology lead for the lower GI tumor stream at Peter MacCallum Cancer Center and senior research fellow within the Division of Personalized Oncology at the Walter and Eliza Hall Institute in Australia. Dr. Tie, thank you so much for joining us today. Jeanne Tie, MD: You’re welcome. Pleasure to OncologyTube: be here. Today we’ll be discussing circulating tumor DNA analysis informing adjuvant chemotherapy and locally advanced rectal cancer. The randomized AGI TG dynamic rectal study, which is being highlighted here…

OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Ghassan K. Abou-Alfa, MD, medical doctor from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College in New York. Dr. Abu Alfa, thank you so much for joining us today. Ghassan K. Abou-Alfa, MD: Thanks so much, Alan. Nice to be OncologyTube: here. Today, we’ll be discussing PROOF 301, results of an early discontinued randomized phase three trial. Dr. Abu Alfa, could you please provide an overview of the PROOF 301 Ghassan K. Abou-Alfa, MD: study? Well, thanks so much, Alan, and, uh, by all means,…

OncologyTube: [00:00:00] Okay, we’re here at ASCO GI 2024 and we have Dr. Ethan Ludmir, medical doctor and the assistant professor, Department of Gastrointestinal Radiation Oncology, Division of Radiation Oncology, the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Ludmir, thank you for joining us Ethan Ludmir, MD: today. Thank you for having me. OncologyTube: Today we’ll be discussing addition of metastasis directed therapy to standard of care systematic therapy of oligometastatic pancreatic ductal adenocarcinoma. Results of a multicenter randomized phase 2 trial, which is being featured here at ASCO GI 2024. So, Dr. Ledmeyer, can you…

OncologyTube: Okay, we’re here at ASCO GI 2024. We have Dr. Manish Shah, medical doctor, and the director of gastrointestinal oncology program at Weill Cornell Medicine in New York. Thank you so much Manish Shah, MD: for joining us today. It’s great to be here. Thank you. OncologyTube: Today, we’ll be discussing first line pembrolizumab plus chemotherapy for advanced esophageal cancer five year outcomes from the Keynote 590 study, a phase three study featured here at ASCO GI 2024. So Dr. Shaw, could you provide an overview of the five year follow up data from the Keynote Manish Shah, MD:…

  OncologyTube: Okay, we’re here at ASCO GI 2024. We have Dr Stacy Cohen, medical doctor and an associate professor of clinical research division at Fred Hutch Cancer Center and University of Washington in Seattle. Dr Cohen, thank you so much for joining us today. Thank you for having me. All right, today we’ll be discussing prognostic value of circulating tumor DNA testing in patients with rectal cancer after neoadjuvant therapy and surgery. Um, a, uh, presentation released here at ASCO GI 2024. So, Dr. Cohen, could you provide a summary of the research on the prognostic implications of, uh,…

Transcript:   Okay, we’re here at ASCO G. I. 2024 and we have Dr. Vivek Sivaya, Medical Doctor, Chief Early Phase Drug Development at the Sarah Cannon Research Institute, Nashville, Tennessee. Dr. Sivaya, thank you so much for joining us today. Thank you so much. Okay, today we’ll be discussing durable efficacy of sulprocatinib in patients with RAT Fusion Plus solid tumors with a focus on GI tumors, the Libretto 001, a study featured here at ASCO GI 2024.So, Dr. Sabaya, could you provide an overview of the Libretto 001 study? The LIBERATO 001 study is a Phase I II…

The full Video OnDemand is now available! This live, virtual, interactive patient education event includes presentations and panel discussions covering general subjects relevant to a diverse range of blood cancers and treatment options. Top medical professionals present patient-focused discussions to help educate the patient and caregiver communities to become advocates for their own health and well-being. Topics include treatment options, side effects, complications, second and third-line treatments, and clinical trials. This event offered an opportunity for a question and answer session with experts about the new information and rapid developments continually emerging in blood cancer treatment options. This version is…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss a RET patient’s risk of recurrence after a lobectomy and chemo. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss immunotherapy treatments for BRAF+ non-smoking patients. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss what first-line treatment options should be for a patient with stage IV disease and no brain mets. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss when patients should consider biomarker retesting, and briefly compare pralsetinib and selpercatinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss current trends toward neoadjuvant TKI treatment options. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss pemetrexed and bevacizumab use in squamous cell lung cancer. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss treatment options for a patient who has developed new brain lesions while on alectinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss using alectinib for a DCTN1 ALK fusion. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss using cabozantinib, and its potential side effects. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss using off-label treatments. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses identifying and treating NRG1 fusions in NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Drs. Stephen Liu and Misako Nagasaka discuss RNA testing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

By. Naval Daver, MD Date: January 12, 2024 Introducing Naval Daver, a faculty member specializing in MD Anderson Cancers in Houston, Texas. As one of the co-chairpersons at a significant conference, Naval values the enriching experience it has offered. During Naval’s presentation, the focus centered on innovative nano-crack-based combination approaches. Specifically, the exploration of novel combinations involving aneroclax with three distinct antibodies—id age in habits, three d one twenty-three antibodies, and three forty-seven antibodies—revealed promising outcomes. These combinations showcased improvements in response rates and survival, indicating optimized durations and dosing for aneroclax and targeted therapy. REGISTER NOW TO JOIN US AT THESE…

By: Parrish Phimes, Date: January 12, 2024 Parrish Phimes, a professor of Intology at the University of Oxford and affiliated with the Oxford University NHS Trust, recently presented insights during an academic gathering. In the conference, Dr. Phimes explored the molecular changes occurring in air cells leading to leukemia, elucidating the underlying mechanisms. Among the aspects of his presentation was an approach to identifying patients likely to respond well or poorly to treatment, specifically chemotherapy and transplantation. Dr. Phimes emphasized the use of genetic changes to categorize patients, distinguishing those expected to have favorable outcomes from those facing challenges in their…

By: Pramilla Krishnamurthy, MD Date: January 12, 2024 Pramilla Krishnamurthy, md, a consultant hematologist at King’s College Hospital in London, engaged in a comprehensive discussion during a recent conference. The focus of her discourse was to scrutinize potential inequities in outcomes for patients diagnosed with AML (Acute Myeloid Leukemia). Dr. Krishnamurthy delved into the intricate interplay of factors contributing to these differential outcomes, highlighting disease biology as a primary determinant. She emphasized the multifaceted nature of the issue, considering variables such as age, with particular attention to teenagers and young adults who might face comparatively worse outcomes. Dr. Krishnamurthy also explored…

By: Priyanka Meta Date: January 11, 2024 Priyanka Meta, a meteorology consultant associated with the University Hospitals of Bristol and Western Managers in the UK, recently presented at a conference on the rare disease BPDCN, also known as plastic plasma cytodendritic cell leukemia neoplasm. Specializing in myeloid diseases, Priyanka discussed historical treatments, challenges, and recent developments in managing BPDCN. During her presentation, she highlighted treatment advances, including Debla Holmes and Degrasse therapies, considered significant in managing the disease. Priyanka also discussed recent developments aimed at improving outcomes for patients with this ailment. REGISTER NOW TO JOIN US AT THESE UPCOMING…

Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the integration of circulating tumor DNA (ctDNA) and Minimal Residual Disease (MRD) assessment as essential elements in shaping medical therapy decisions. In Dr. Mchayleh’s perspective, leveraging ctDNA and MRD can serve as a determinant in adjusting the intensity of treatment protocols.During his address at MDAS, Dr. Mchayleh highlights the potential of ctDNA as a tool for MRD monitoring and early recurrence detection. Expressing concern that this approach is currently underused, he stresses the importance of incorporating ctDNA and MRD analyses at the early stages of treatment.…

In a discussion on cancer science, Wassim Mchayleh, MD, explores the role of Minimal Residual Disease (MRD). Dr. Mchayleh discusses the application of MRD in colorectal and breast cancer, highlighting its ability to predict early recurrence before radiologic signs appear, as evidenced in various trials. He emphasizes the sensitivity of MRD testing in detecting early recurrence.Dr. Mchayleh advocates for a proactive approach to using MRD in the neoadjuvant setting for early breast cancer. He envisions a shift where MRD not only predicts treatment responses but also influences therapeutic strategies based on MRD outcomes, particularly gauging the clearance of plasma during…

David J. Andorsky, MD, an Associate Chair for US Oncology Hematology Research and a member of the Rocky Mountain Cancer’s Research Executive Committee, is scheduled to participate in an upcoming interview. During this discussion, he will provide insights into his recent study, titled “Recent Patterns of Care with BTK Inhibitors and Distribution of Social Determinants of Health Among Patients with CLL / SLL in the US Community Setting.”In the interview, Dr. Andorsky will offer an overview of the study, highlighting changes in the treatment landscape of BTK inhibitors for CLL / SLL. Specifically, he will discuss variations in the use…

Dipti Patel-Donnelly, a medical oncologist at the Virginia Cancer Specialists, leads a study titled “How Can We Manage High-Risk Hematologic Malignancies in the Community?” The study investigates the impact of integrating novel agents, BiTe therapy, CAR-T, and transplantation into the standard of care for hematologic malignancies in community settings.Dr. Patel-Donnelly shares insights based on her experience, discussing the challenges and opportunities associated with implementing advanced therapies in local cancer care. The educational session emphasizes the need to address access issues for patients with hematologic malignancies in the community, focusing on specific diagnostic, supportive, and treatment challenges in acute leukemia, high-grade…

In the realm of advancements in CAR T-cell therapy for relapsed/refractory mantle cell lymphoma (MCL), Dr. Brian Hill, MD, PhD, stands at the forefront to discuss the findings of the ZUMA-2 and ZUMA-18 studies. The ZUMA-2 study reported a median overall survival (OS) of 46.4 months with brexu-cel, showcasing its efficacy in patients with relapsed/refractory MCL and a complete response (CR). Dr. Hill will explore the implications of these findings, contributing to the evolving landscape of CAR T-cell therapy for MCL. Moreover, he will discuss considerations surrounding the durability of response observed in these patients, adding a dimension to the…

Al-Ola Abdallah, MD, Associate Professor of Medicine at The University of Kansas, conducted a study titled Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy. The research indicates comparable response rates in Daratumumab-naïve (DN) and Daratumumab-refractory (DR) patients, with a notable difference in median overall survival (OS). The study explores potential reasons for the higher OS in the DN group and discusses the impact of these findings on treatment decisions for highly refractory multiple myeloma patients. The research also notes similar treatment-related toxicities between DN and DR groups but observes a higher rate of rehospitalization…

John F. Seymour, MBBS, Ph.D., FRACP, a clinical haematologist and the Director of the Haematology Department at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, VIC, Australia, conducted a groundbreaking Phase 1 study on BGB-16673, a pioneering Bruton tyrosine kinase (BTK) degrader. The focus of this study was on patients grappling with relapsed or refractory B-cell malignancies, particularly those who had faced disease progression despite undergoing treatment with BTK inhibitors. The study aimed to delve into the unique mechanism of action of BGB-16673, specifically highlighting the chimeric degradation activating compound (CDAC) structure responsible for BTK degradation. Understanding this…

Asya Nina Varshavsky-Yanovsky, MD, PhD, serves as an Assistant Professor within the Department of Bone Marrow Transplant and Cellular Therapies. The study, “Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies,” led by Dr. Varshavsky-Yanovsky, delves into the efficacy and safety of elranatamab in Black or African American patients grappling with relapsed/refractory multiple myeloma (RRMM). This investigation explores critical metrics such as the overall response rate (ORR) and median duration of response (DOR). Notably, elranatamab exhibited a promising ORR of 58.3% and a median DOR of 18.4 months among…

In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology, investigates a combination therapy for treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL) patients. The study focuses on the safety and efficacy of combining Sonrotoclax, a second-generation BCL2 inhibitor, with Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor. Preliminary results suggest outcomes, with a focus on responses, tolerability, and safety.The combination of Sonrotoclax and Zanubrutinib presents an advancement in the treatment landscape for TN-CLL/SLL patients. Compared to existing treatments, this combination demonstrates potential advantages, including a safety profile with manageable treatment-emergent adverse events. Dr. Tam explores aspects…

Hamish Scott, MD, serves as the Head of the Department of Genetics and Molecular Pathology at SA Pathology in Adelaide, Australia. In collaboration with his colleague, Chris Hahn, MD, who heads the Molecular Pathology Research Laboratory, Dr. Scott shares insights into a groundbreaking study during an interview. The research stemmed from a case involving a family with thrombocytopenia and neutropenia, where the mother developed acute myeloid leukemia and myelodysplastic syndrome.Their investigation led to the discovery of a novel predisposition gene, ERG, associated with bone marrow failure and hematological malignancies. The study uncovered a missense mutation in the ERG gene among…

Rabi Hanna, MD, from the Department of Pediatric Hematology Oncology and BMT at Cleveland Clinic Children’s, conducted a study on AsCas12a gene editing with EDIT-301 for severe Sickle Cell Disease (SCD) and transfusion-dependent β-thalassemia (TDT). The research aimed to evaluate the efficacy of this approach in achieving normalization of hemoglobin levels and increased production of fetal hemoglobin (HbF) in affected patients.The results of EDIT-301 in patients with severe SCD and TDT contribute to the growing field of gene-edited therapies for hemoglobinopathies. This novel approach, targeting HBG1/2 promoters, has potential for outcomes in patients with these conditions, advancing our understanding of…

Evandro Bezerra, MD, hematologist and assistant professor at The Ohio State University Wexner Medical Center, leads research focused on improving the outcomes of patients with hematologic malignancies. The study, Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia (B-cell ALL): Evidence from the CIBMTR Registry, delves into the real-world outcomes of brexucabtagene autoleucel, known as brexu-cel, for adult patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-cell ALL).Intriguingly, the study reveals that a substantial 91% of the patients included would have been ineligible for the ZUMA-3 trial. This raises important questions about…

In the groundbreaking study conducted by Bruce Feinberg,DO, Chief Medical Officer at Cardinal Health, the focus is on investigating the efficacy of Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting.The study delves into the real-world treatment patterns and outcomes of patients grappling with relapsed/refractory DLBCL who have undergone tafasitamab treatment within community oncology settings. A key objective is to draw comparisons between these findings and the results observed in the L-MIND clinical trial.Dr. Feinberg’s research particularly emphasizes a racially and ethnically diverse patient population, with a notable representation from typically underrepresented…

At ASH 2023, Hamza Hashmi, MD, a medical doctor and hematologist from Charleston, South Carolina, discussed a multicenter study focusing on the toxicity and efficacy outcomes associated with Teclistamab in patients above the age of 70 with relapsed refractory multiple myeloma.The retrospective analysis included nearly 100 patients, with around one-third of them aged 70 or above. Dr. Hashmi highlighted the challenges faced by older patients, such as compromised physical performance status, organ dysfunction, renal issues, and other high-risk disease features. Over a median follow-up of approximately three and a half months, the study revealed comparable safety and efficacy outcomes between…

Catherine Diefenbach, MD, a Hematologist and Medical Oncologist at NYU Langone Health, led a study titled “Results from an Intergroup Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412).”This Phase II study investigated the efficacy and safety of combining immune checkpoint blockade with the CD30-targeting antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Classic Hodgkin lymphoma (cHL).The study’s importance lies in its approach to addressing the challenges of cHL treatment. By combining immune checkpoint inhibitors (Ipilimumab and Nivolumab) with brentuximab vedotin,…

In an interview, Andrew Evens, DO, an expert in hematology and oncology, will discuss a study on predicting progression-free survival (PFS) in early-stage Hodgkin lymphoma (E-HL). Dr. Evens, a seasoned researcher and clinician, will provide insight into the E-HIPI model, which identifies factors such as nodal location, sex, and key continuous variables as essential in prognosticating PFS.When asked for a brief overview of the study, Dr. Evens will share insights into the research’s significance and potential implications for oncology. Regarding the E-HIPI model, he will elaborate on how factors like nodal location, sex, and key continuous variables contribute to predicting…

In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics in pediatric ALL patients. The research aims to predict long-term responses to anti-CD19 CAR T cells by analyzing gene expression profiles. Dr. Melenhorst reveals a cytogram profile linked to B cell replacement, a key remission biomarker. The interview explores correlations in CAR T cells’ functionality, emphasizing the potential for manipulation to enhance efficacy. Insights from a mouse model underscore the importance of the type 2 pathway in sustaining remission, offering perspectives for CAR T therapy development.

Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab) + KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone. The discussion covered the clinical significance of achieving minimal residual disease (MRD) negativity, with Zandra correlating the depth of response to long-term outcomes. She expressed cautious optimism for the high-risk patient population, highlighting the need for extended follow-up. Safety and tolerability considerations were addressed, with Zandra acknowledging numerical imbalances in deaths and emphasizing the importance of awaiting further survival results. ASH 2023 witnessed an…

At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at the Sylvester Comprehensive Cancer Center, University of Miami, engaged in a discussion about the final analysis of the Sinterra study. The study, a randomized phase two trial, aimed to assess the efficacy and safety of daratumumab monotherapy in patients with intermediate or high-risk smoldering multiple myeloma.Dr. Landgren outlined the international multicenter nature of the trial and its objective to investigate whether daratumumab could delay or prevent the progression from smoldering myeloma to multiple myeloma.

Under the lights of ASH 2023, the microphone poised to capture insights, Dr. Lorenzo Falchi, a medical doctor and lymphoma specialist at Memorial Sloan Kettering in New York, engaged in a conversation.Navigating the pronunciation of a treatment, Dr. Falchi provided an overview of Mosunetuzumab’s role as a first-line therapy for high tumor burden follicular lymphoma, based on the initial results from a multicenter phase 2 study.Dr. Falchi unfolded the narrative behind the study, emphasizing its roots in addressing the limitations of traditional chemotherapy. He highlighted the study’s optimism, revealing Mosunetuzumab’s high deliverability and patient tolerance. The efficacy results were promising,…

At ASH 2023, Katherine Broome, MD, a medical doctor and medical oncologist at the Georgetown Lombardi Comprehensive Cancer Center at MedStar Health, provided details about a study focused on the time to achieve platelet count response after intravenous Fc-gamma receptor antagonist (Efgartigimod) in adults with primary immune thrombocytopenia.This phase three multicenter double-blind placebo-controlled randomized clinical trial involved multiple countries and targeted adult patients aged 18 or older diagnosed with ITP for a minimum of three months. Dr. Broome explained that these patients had failed at least one therapeutic intervention and were either not responding to their second intervention or had…

By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical doctor and professor of medicine at Stanford University School of Medicine, shared captivating insights into the transformative landscape of lymphoma treatment during an interview. The discussion centered around the pivotal TRANSFORM study, introducing Lysocabtagene maraleugel as a second-line therapy for large B cell lymphomas resistant to frontline treatments. Dr. Alizadeh eloquently elaborated on the trial’s resounding success, emphasizing its profound shift towards personalized therapies and the abandonment of traditional methods like high-dose chemotherapy and transplantation. The interview seamlessly transitioned into a sub-study, exploring the role…

By. Valeria Santini, MDDate: 12/13/2023At the ASH 2023 symposium, Valeria Santini, MD, a distinguished medical doctor and associate professor of hematology from the University of Florence Medical School in Italy, engaged the audience in a discussion about the Phase 3 Medalist study.Dr. Santini commenced her presentation by providing a comprehensive overview of the Medalist trial initiated in 2016. This clinical investigation focused on assessing the response to Luspatercept, an active erythroid maturation agent. The study specifically targeted lower-risk myelodysplastic syndromes (MDS) patients with transfusion dependence who were refractory or ineligible for conventional erythropoietic stimulating agents.The trial involved the administration of…

By. Robert Rifkin, MDDate: 12/13/2023 Robert Rifkin, MD, a medical oncologist and hematologist at SCRI in Rocky Mountain Cancer Centers, part of the U.S. Oncology Network, for a discussion about a phase two study on the outpatient administration of Teclistamab, a bispecific antibody targeting BCMA in patients with multiple myeloma. Dr. Rifkin explains that the study aims to bring new classes of myeloma drugs into the clinic and community more practically. Teclistamab, being the first bispecific antibody released for multiple myeloma, initially mandated hospitalization due to concerns about cytokine release syndrome (CRS) and neurologic dysfunction. The study seeks to introduce…

By. Halle Moore, MD Date. 12/13/2023 Halle Moore, MD, the Medical Doctor and Director of Breast Medical Oncology and Co-Director for the Comprehensive Breast Cancer Program at Cleveland Clinic, shares insights into a study focusing on fertility preservation and assisted reproductive technologies in breast cancer patients who interrupt endocrine therapy to attempt pregnancy.Dr. Moore discusses the eligibility criteria for women in the study, emphasizing factors such as age, stage of breast cancer, and duration of adjuvant endocrine therapy. The study, aimed at assessing the short-term safety of interrupting endocrine therapy for pregnancy, explores outcomes related to assisted reproductive technology and…

By. Saranya Chumsri, MD Date: 12/12/2023 Saranya Chumsri, MD, an expert in the field of triple-negative breast cancer (TNBC), will provide answers to questions during the interview. The discussion will cover the significance of evaluating immune landscapes in TNBC, the use of technologies such as NanoString IO360 and Digital Spatial Profiling, the association between immune-related proteins and different landscapes, the exploration of the PI3K-Akt signaling pathway, and the implications of single-cell sequencing findings on targeted therapies. Dr. Chumsri’s insights aim to offer objective perspectives on understanding TNBC and guiding potential treatment strategies.

Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a medical oncologist from the University of North Carolina Chapel Hill. Graciously taking the time to engage in conversation, Allen extended his gratitude to Dr. Abdou for joining the discussion.In their exchange, the focus shifted to the intricate realm of medical practice, specifically exploring the practice patterns associated with the sequential use of antibody drug conjugates after antibody drugs. Dr. Yara Abdou delved into the complexities of this topic, shedding light on the challenges faced by providers in sequencing these drugs due to the yet-to-be-fully-understood efficacy…

By: Ibrahim Aldoss, MD – City of HopeDate: 12/11/2023Revumenib Monotherapy in KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study

At ASH 2023, there is a discussion with Dr. Davide Matino, Assistant Professor of Medicine at McMaster University, shedding light on the groundbreaking findings from the phase three basis trial concerning the anti-tissue factor pathway inhibitor, Marstacimab. The conversation delves into the study’s design and outcomes, focusing on a cohort of patients with severe hemophilia A or moderately severe to severe hemophilia B without inhibitors.Dr. Matino provides a comprehensive overview of the study, detailing the observational phase, loading doses, and subsequent treatment phases involving Marstacimab. The emphasis is on the subcutaneous administration of the drug, representing a pivotal advancement in the…

Allen Wilbanks stands at the forefront of SABCS 2023, the setting for a conversation with Thomas Budd, MD, a medical doctor and oncologist from the Cleveland Clinic Cancer Center. In this discussion, Allen introduces the focus—the Phase 1 trial of the Alpha-Lactalbumin vaccine in high-risk operable triple-negative breast cancer (TNBC) patients and those with a genetic predisposition to TNBC.Dr. Budd elaborates on the primary objectives of the trial, emphasizing the critical role of determining the appropriate vaccine dosage for future applications. The trial evaluates toxicity, primarily manifested as local injection site reactions, and measures immune responses through Alispot assays. The…

Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr. Adam Brufsky, a medical doctor, professor of medicine, and associate chief division hematology, oncology, and co-director of the Comprehensive Breast Cancer Center at the University of Pittsburgh.In the interview, Allen queries Dr. Brufsky about the real-world effectiveness of Palbociclib, or palbociclib, in combination with aromatase inhibitors for metastatic breast cancer patients with cardiovascular disease. Dr. Brufsky delves into the key findings of the study, highlighting the analysis of patients who were not part of clinical trials, and emphasizing the significance of real-world evidence.The study, known…

Wassim Mchayleh, MD, an expert in oncology, participated in the SABCS 2023 conference, offering insights into the latest developments in breast cancer research.Regarding groundbreaking findings or emerging trends at SABCS 2023, Dr. Mchayleh discussed studies potentially impacting clinical practices in breast cancer management, including novel therapeutic approaches and advancements in targeted therapies.In the area of cutting-edge technologies, Dr. Mchayleh addressed abstracts on precision medicine, genomics, and other innovative approaches in breast cancer research.The conversation then turned to a special feature on Minimal Residual Disease (MRD) testing. Dr. Mchayleh answered questions on the utility of MRD testing and its significance in…

Jeff Sharman, MD, a medical oncologist at the Willamette Ballet Cancer Institute and Research Center, also serving as the Medical Director of Hematology Research at the Sarah Cannon Research Institute.Phase 3 Elevate TN trial, a focus of Sharman’s work. The trial, designed for previously untreated chronic lymphocytic leukemia patients, included three arms: a control arm with Obinutuzumab chlorambucil, and two experimental arms with either acalabrutinib monotherapy or a combination of acalabrutinib with obinutuzumab. Sharman reveals that the study resulted in FDA approval for acalabrutinib in previously untreated patients.During the discussion, Sharman unveils key findings from the six-year follow-up study. Notably,…

Allen Wilbanks stood alongside Alina Hamilton, PhD, at the SABCS 2023 event, where they delved into groundbreaking research on breast cancer immunotherapy. Alina Hamilton, a postdoctoral research associate in the cancer control education program at the Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, shared insights on her work.Motivated by the alarming 41 percent higher breast cancer mortality rate among black women, Hamilton explored Survivin as a potential immunotherapy target. Survivin, a protein in the inhibitor of the apoptosis pathway, showed associations with aggressive tumor features, especially in breast cancer. Despite smaller and less diverse previous studies, Hamilton…

By: Melinda Telli, MD, Date: 12/9/2023 At the SABCS 2023 conference, we had the privilege of interviewing Melinda Telli, MD, a medical doctor, associate professor of medicine at Stanford University School of Medicine, and the director of the breast cancer program at Stanford Cancer Institute. Dr. Telli shared insights on recent advances in triple-negative breast cancer (TNBC) during a session she presided over.In the interview, Dr. Telli discussed progress in TNBC treatment and management, emphasizing that breakthroughs have occurred in the past five years. She traced the evolution of TNBC understanding since its first description in 2005, highlighting milestones such…

By: Hope Rugo, MD Date: 12/9/2023 At the SABCS 2023 conference, medical oncologist Hope Rugo from the University of California, San Francisco, engaged in a comprehensive discussion with interviewer Allen Wilbanks about the Keylink 009 study. Hope Rugo shared insights into the randomized open-label phase 2 trial, which aimed to assess the efficacy of the combination of Pembrolizumab and Olaparib as maintenance therapy for patients with triple-negative breast cancer (TNBC) receiving chemotherapy and Pembrolizumab.The trial enrolled patients with metastatic or locally advanced unresectable TNBC who had not undergone prior treatment in the metastatic setting. The treatment protocol involved induction chemotherapy…

By: Yara Abdou, MD, Date. 12/08/2023 At SABCS 2023, Yara Abdou, MD, a medical oncologist from the University of North Carolina Chapel Hill, discusses a phase one clinical trial titled “Translational Insights from a Phase One: First in Human Clinical Trial of the Anti-HER2.”In this trial, the focus is on CAR macrophages, a therapy for solid tumors expressing HER2, with 57 percent being breast cancer patients. Dr. Abdou explains the process: patients undergo leukophoresis to obtain monocytes, differentiated into macrophages, and transduced with an adenoviral vector to polarize the macrophage into an M1 phenotype. The CAR gene is encoded, and…

By: Hatem Azim, MD Date. 12/08/2023At SABCS 2023, a discussion on fertility preservation and assisted reproductive technologies in breast cancer patients interrupting endocrine therapy to attempt pregnancy. The speaker for this session was Hatem Azim, MD, a medical doctor, medical oncologist, and adjunct professor at the School of Medicine of the Monterey Institute of Technology. Additionally, Hatem Azim holds the position of Senior Oncology Faculty at the College of the European School of Oncology.Opening the conversation, Allen Wilbanks acknowledged Hatem Azim’s expertise and expressed gratitude for his presence in the discussion. Hatem Azim delved into the key findings from the positive trial…

Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MDTranscript (spelling not corrected)Yara Abdou, MD – Treatment differences by race and age in metastatic hormone receptor-positive/HER2- with Yara Abdour, MD 
Allen Wilbanks: [00:00:00] Okay, we’re here at S. A. B. C. S. 2023 and we’re lucky enough to have Dr Yara Abdu, a medical oncologist at the University of North Carolina Chapel Hill. Thank you so much for sitting down with us. 
Yara Abdou, MD: Absolutely. Thank you for having me. So 
Allen Wilbanks: today we’re gonna be discussing treatment differences by race and age and…

By: Julie Lang, MD Date. 12/07/2023Julie Lang, MD, a medical professional known for expertise in breast cancer research, has developed the Mechanical Conditioning Score (MCS), a test for identifying early-stage breast cancer patients with potential poor prognoses.The MCS evaluates mechanical factors and markers in breast tissues, such as tissue stiffness, cellular alignment, and extracellular matrix composition. It aids in predicting patient prognoses and informing treatment decisions.In terms of antifibrotic therapy, Lang’s research identifies how the MCS determines patients likely to respond to such interventions. By pinpointing individuals with increased tissue stiffness and fibrotic changes, the MCS becomes a tool for…

By. Terry Mamounas Date: 12/07/2023In a collaborative study between NVP and RT, led by oncologist Terry Mamounas, MD, the NSABP B-51/RTOG 1304 trial aimed to assess the role of local-regional radiotherapy in patients with initially positive axillary nodes that turned negative after neoadjuvant chemotherapy.The study objectives were to evaluate the necessity and potential benefits of local-regional radiotherapy in this specific patient population, focusing on the impact on invasive breast cancer recurrence-free interval (IBCF RFI). The study design incorporated a randomized comparison between patients receiving local-regional radiotherapy and those not, ensuring a thorough assessment of treatment effectiveness.Patient characteristics and demographics in…

By. Joanne Kotsopoulos, MD, Date: 12/07/2023 At the SABCS 2023 conference, Joanne Kotsopoulos, MD, a researcher from the Women’s College Research Institute in Toronto, engaged in a discussion with Allen Wilbanks. The focus of their conversation was on the cancer risk associated with exogenous hormone use in women with inherited BRCA1 or BRCA2 mutations, a topic Kotsopoulos has extensively researched.In her presentation, Kotsopoulos provided an overview of the complex relationship between exogenous hormones, such as oral contraceptives and hormone replacement therapy, and the risk of breast and ovarian cancer in mutation carriers. She delved into the existing evidence, including both established…

By: Virginia Kaklamani, MD Date: 12/8/2023 Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology and Oncology at UT Health San Antonio and the leader of the breast cancer program at UT Health San Antonio MD Anderson Cancer Center, engaged in a conversation at SABCS 2023. Kaklamani shared insights on the highlights and trends observed during the event. Discussing various themes, the conference explored prevention strategies for breast cancer on chemopreventive strategies and estradiol level assessments to identify high-risk individuals. The discussions extended to advancements in early-stage treatment, exploring topics such as radiation therapy necessity and axillary…

By. Kellogg Parsons, MD Date: 12/07/2023 Kellogg Parsons, MD, a medical doctor and Vice President of Clinical Development at Embrace Therapeutics, joins him. As the interview unfolds, Dr. Parsons shares insights into the preclinical data of MBRC 101, a drug targeting the receptor tyrosine kinase.In their discussion, Dr. Parsons discusses the applications of MBRC 101 in advanced metastatic solid tumors, particularly in breast cancer subtypes like triple-negative and H.R. positive HER2-negative. The uniqueness of EphA5, highly expressed in cancer cells with minimal presence in normal tissues, makes it a prospect for targeted cancer therapy.Moving on to the pharmacokinetic aspects, Dr. Parsons…

By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the use of CDK4/6 inhibitors in the treatment of metastatic ER+ breast cancer. As an authority in the field, Dr. O’Regan provides perspectives on the ongoing debate regarding the similarities and differences among these inhibitors and their impact on patient outcomes.The first question explores the debate on whether CDK4/6 inhibitors exhibit distinct characteristics in terms of efficacy, given their known improvements in progression-free survival and overall survival. Dr. O’Regan discusses the nuances of this debate, providing an understanding of the variations among these inhibitors and their…

By. Neil Carleton, MD Date. 12/07/2023 In the interview with Neil Carleton, MD, the discussion revolved around the age-related remodeling of the systemic and breast microenvironment and its implications for promoting a tumor-permissive environment in ER+ breast cancer, as presented in recent research. Dr. Carleton expertly elaborated on the significance of factors beyond accumulating mutations, such as changes in estrogen disposition, inflammation, and immune contexture, in contributing to the age-related nature of ER+ breast cancer. He emphasized the potential impact of understanding these factors on future approaches to cancer prevention and treatment in older women.As the conversation delved deeper, Dr. Carleton…

By: Carol Fabian, MD Date. 12/07/2023 In an interview, Carol Fabian, MD, an expert in breast cancer research and prevention, will discuss critical aspects of breast cancer risk assessment and prevention. She will address the utility of polygenic risk scores, explaining how they complement imaging and influence decisions regarding risk reduction therapy.Dr. Fabian will provide information on hormone replacement and alternatives for women at moderate to high risk of developing breast cancer. She will discuss safe alternatives considered in this context, focusing on choices aligned with patient safety and well-being.The conversation will touch upon the presentation by Dr. Joanne Kotsopoulos, focusing…

By: Joyti Bajpai, MD Date: 12/07/2023 In a forthcoming interview, Jyoti Bajpai, MD, a renowned expert in the field, will explore the nuances of the Olanzapine-3 study, focusing on the comparison between low-dose and standard-dose Olanzapine in triple antiemetic therapy for highly emetogenic chemotherapy in solid tumor patients. Dr. Bajpai will provide insight into the significance of the Olanzapine study, shedding light on the impact of the combination therapy involving Olanzapine on complete response rates in patients undergoing highly emetogenic chemotherapy regimens. The interview will explore the potential breakthroughs this study presents for improving patient outcomes. The discussion will pivot…

By. Anjali Advani, MD Date. 12/06/2023 In this conversation on OncologyTube, viewers can explore the SWOG 18 clinical trial with host Allen Wilbanks and Dr. Anjali Advani, a medical oncologist and professor at the Cleveland Clinic. The discussion centers on the long-term follow-up data of combining dasatinib, prednisone, and blinatumomab for the treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in older patients.Dr. Advani, the director of the inpatient leukemia program at the Cleveland Clinic, provides insights into the eligibility criteria for the study, specifically focusing on older patients with Ph+ ALL. The conversation delves into the treatment protocol’s…

By: Anjali Advani, MD Date: 12/06/2023 Dive into this insightful conversation with Dr. Anjali Advani, a distinguished medical oncologist and professor specializing in hemologic oncology and blood disorders at the Cleveland Clinic. Dr. Advani serves as the director of the inpatient leukemia program at the Tosset Cancer Institute. The discussion centers around groundbreaking research on Brexucabtagene Autoleucel therapy in adults with relapse refractory cells.Opening the conversation, Allen introduces Dr. Advani and expresses gratitude for her presence on the show. The dialogue delves into the significant response rates observed in adults treated with Brexucabtagene Autoleucel therapy. Dr. Advani emphasizes the real-world…

By. Fairooz F. Kabbinavar, MD, FACP​ Date. 12/06/2023 Fairooz F. Kabbinavar, MD, FACP, a medical oncologist with a background in academia and drug development, began his journey at Harvard in Boston, culminating in a hematology oncology fellowship at UCLA. During his 25-year tenure at UCLA, he rose to the rank of full professor of medicine and medical oncology, receiving an endowed chair for his contributions to clinical cancer research. Dr. Kabbinavar’s commitment to advancing cancer therapeutics, particularly in new drug development, led him to join Genentech and subsequently other biotech companies. His pivotal role in the development and approval of…

By. Josina Reddy, MDDate. 11/24/2023Today, the focus is on the ALINA trial, a phase three study comparing Alectinib versus chemotherapy as adjuvant therapy for patients with stage 1B to 3A ALK-positive non-small cell lung cancer. Presented in 2023, the trial results are discussed by Josina Reddy, MD. The significance of the phase 3 ALINA results lies in the 76% reduction in the risk of disease recurrence or death with Alectinib compared to platinum-based chemotherapy in ALK-positive early-stage non-small cell lung cancer.Josina Reddy, MD, explains that the ALINA trial enrolled patients with early-stage lung cancer that could be surgically removed, specifically…

By. Allen WilbanksDate. 11/23/2023Lot Aronson, MD, a medical doctor and researcher from the Department of Gynecologic Oncology in the Netherlands Cancer Institute, engaged in a discussion with Allen Wilbanks of Oncology Tube. The focus was the updated 10-year survival analysis from the OVHIPEC-1 trial, exploring the effects of cytoreductive surgery with or without hypothermic intraperitoneal chemotherapy (HIPEC) in patients with advanced ovarian cancer.Aronson initiated the conversation by providing an overview of the trial’s design, emphasizing its initiation in 2006 and subsequent publication in 2018. The OVHIPEC-1 trial, an open-label, randomized controlled phase three study, recruited patients from specialized centers in…

By. Anusha Kalbasi, MDDate. 11/22/2023In a recent discussion on adoptive T cell therapies for solid tumors, Anusha Kalbasi, MD, provided a comprehensive analysis of various modalities, shedding light on their challenges and potential breakthroughs. Kalbasi began by delving into the realm of tilt therapy, a longstanding approach for melanoma patients. Over the last decade or two, industry interest has surged, revealing response rates of 30 to 50 percent in heavily pretreated melanoma patients. The comparison with immune checkpoint blockade, particularly ipilimumab, has demonstrated promising data on tilt therapy’s longer progression-free survival.The conversation then shifted to TCR-engineered therapy, where Kalbasi elucidated…

By. Bridget Keenan, MDDate. 11/22/2023Bridget Keenan, MD, discusses the tumor microenvironment (TME) and its crucial role in cancer immunotherapy responses. Dr. Keenan notes that effector T cells align with positive outcomes, while suppressive myeloid cells and cytokine signals within the TME often signify a less favorable prognosis and resistance to immunotherapy.During the presentation, Dr. Keenan explores targeting the TME through immunotherapies, focusing on tumor metabolism and immunosuppressive myeloid cells. Despite various drugs aiming at the TME, no standout winner has emerged, prompting Dr. Keenan to discuss potential strategies for more effective interventions.She highlights exploring metabolic byproducts with higher concentrations in…

By. Bartosz Chmielowski, MD PhDDate: 11/22/2023In this presentation, Bartosz Chmielowski, MD PhD, discusses advancements in cancer therapy, focusing on approaches utilizing herpes virus-based treatments. The spotlight is on T VEC, the pioneering herpes virus therapy for cancer patients. The approval of this therapy was based on the durability of responses observed during clinical trials, demonstrating a heightened response rate compared to G-M-C-S-F injections alone.Bartosz Chmielowski, MD PhD, emphasizes the specificity of T VEC, clarifying that it is tailored for patients with easily injectable diseases, limited to skin lesions or palpable lymph nodes. The therapy showcased a borderline improvement in overall…

By. Anna M. Wu, MD, PhDDate. 11/21/2023Anna M. Wu, MD, PhD, discussed the use of immunotherapy in patients who underwent melanoma resection and reviewed drug development strategies in this field. She traced the progression from treating advanced, unresectable cases to improved outcomes in stage three and node-negative diseases.Wu highlighted the shift from post-surgery to pre-surgery immunotherapy, citing the S1801 clinical trial’s significant improvement in event-free survival with pre-surgery treatment. She discussed ongoing trials and emerging data on effective combinations, including early outcomes of a cancer vaccine in melanoma.Regarding the future of immunotherapy, Wu mentioned combining drugs like nivolumab and melatomab…

By. Arta Monjazeb, MDDate: 11/21/2023Arta Monir Monjazeb, MD, explores cancer immunotherapy with a detailed discussion on the immune response, radiation’s role, and the challenges of combining radiotherapy with immune checkpoint inhibitors (ICI). As a prominent figure in the field, Dr. Monjazeb brings forth insights that bridge clinical practice and research.In an exploration of the immune response, Dr. Monjazeb emphasizes the role of antigen-presenting cells in transitioning from innate to adaptive immunity. He discusses the intricate relationship between radiation and the immune system, emphasizing the importance of immunogenic cell death and the subsequent activation of T cells.Touching upon disparities among cancer…

By. Greg Daniels, MD Date: 11/21/2023 In this discussion, Dr. Greg Daniels, a physician in the field of solid organ transplantation, provides information on the complexities faced by transplant patients, particularly those who have undergone kidney or heart transplants. With experience, Dr. Daniels emphasizes the role of immune suppressive drugs in maintaining the viability of transplanted organs, preventing rejection by the recipient’s body.Dr. Daniels elucidates the various immune suppressive agents used, highlighting the differences among them. Notably, he underscores the risk of cancer, particularly skin cancers such as cutaneous squamous cell carcinoma, as a concern for transplant patients. The physician…

By. Katy Tsai, MDDate: 11/21/2023Katy Tsai, MD, discusses the progress in cancer survivorship on a national scale, citing data from the American Cancer Society projecting a significant increase in the number of cancer survivors in the United States over the next decade. Katy Tsai, specializing in treating advanced melanoma skin cancer patients, reflects on advancements in melanoma survivorship with the introduction of immune checkpoint inhibitors.In her dialogue, Katy Tsai delves into the historical context, emphasizing the shift from dire prognoses for metastatic melanoma patients to outcomes with contemporary treatments. She specifically mentions the success of combination immune checkpoint inhibitor blockade,…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu gives an overview of treatment options for patients with NTRK+ NSCLC and what some side effects may be. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses recent developments in RET+ NSCLC treatment, including next-generation RET TKIs. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu compares selpercatinib and pralsetinib as treatment options for patients with RET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses Pralsetinib as a treatment option for RET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses Selpercatinib as a treatment option for RET+ disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Stephen Liu discusses how RET fusions are detected, and discusses methods of treatment, including Selpercatinib and Pralsetinib. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Misako Nagasaka details treatment options and study data for patients with ROS1+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Misako Nagasaka gives an in-depth discussion on ALK+ NSCLC, from possible treatment options to study data. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses the importance of knowing genetic testing results regardless of PD-L1 level. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses if there’s a reason some patients can remain on TKIs for extended time without developing resistance. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses methods of delivering SBRT, including CyberKnife. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses current understanding of what can cause lung cancer, and prevention methods. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses how patients can advocate for biomarker testing. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses local therapy options for patients with oligoprogression, and in particular, radiofrequency ablation for adrenal nodules. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses what a patient should discuss with their doctor if they progress on a targeted therapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses trial and treatment information for rare lung cancer mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses the importance of biomarker testing even in early stage NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses targeted therapy options for patients who have driver mutations. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses whether or not adding radiation will increase toxicity in patients who are already receiving targeted therapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, the panel discusses options for SBRT administration, and if treatment is affected if a patient is unable to hold their breath. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar discusses local therapy options for patients with metastatic disease who have received a front-line therapy. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience and a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar examines what has been learned from studies, what still remains unanswered, and future directions of local therapy treatments for patients with NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: #Takeda #Janssen #Lilly #Genentech #Mirati #ExactSciences #BMS #GEHealthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar discusses local therapy treatment options for patients who have oligoprogressive disease. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT). For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar discusses the concept of using local therapy as an additional treatment for limited metastatic NSCLC, including Stereotactic Body Radiation Therapy (SBRT). For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Puneeth Iyengar looks at current statistics for methods of adding to targeted therapy, as well as giving an overview of biology in treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses what the patient can do to advocate for themselves during treatment. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses treatment options for patients with locally advanced NSCLC, and how to proceed while waiting for trial data. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses considerations and questions for targeted therapy before surgery. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss explains why immunotherapy is not typically given to patients with resectable NSCLC and a driver mutation. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss gives a brief description of the ongoing Alina trial for patients with ALK+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss examines important details learned during the ADAURA trial, including overall survival, reduced risk of brain mets, and side effects. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Joshua Reuss discusses the ADAURA trial, which suggested Osimertinib as a treatment for EGFR+ NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai discusses the administration of therapy for biomarkers, and how to overcome the gaps in administration, access, and affordability. For more, please visit http://cancerGRACE.org/. To watch the complete video click here: https://www.youtube.com/watch?v=v85bJi-vtGM&t=3939s BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE…

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai discusses how to address the issues of cost and insurance approval when obtaining biomarker testing. For more, please visit http://cancerGRACE.org/. To watch the full video click here: https://www.youtube.com/watch?v=ksZ6w3CEdPg BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

Leading oncologists come together in this recorded live event to discuss targeted therapy options for patients with lung cancer. This includes a Q&A with the audience, as well as a presentation by a patient advocate, Ivy Elkins. In this video, Dr. Aakash Desai emphasizes the importance of physicians ordering biomarker testing for patients with NSCLC. For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum. BenSound File Name: Sweet (BenSound.com) BenSound License #: DSSHUIYGV4VQCETM Thank you to our sponsors: Takeda, Janssen , Lilly, Genentech , Mirati, Exact Sciences, BMS, and GE Healthcare.

By. Nicolas Rigard, MDDate. 11/20/2023In this interview, Nicolas Girard, MD, a medical doctor and professor of respiratory medicine at Versailles, St. Quentin University, and the head of the Curie-Montsouris Thorax Institute, discusses the PAPILLON study. The interview, conducted by Alan from OncologyTube, explores the comparison between Amivantamab plus chemotherapy and chemotherapy alone as the first-line treatment for EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer.Nicolas Girard, MD, provides an overview of the study’s primary endpoint, progression-free survival (PFS), emphasizing the reduction in the risk of disease progression and the extension of median PFS with the Amivantamab plus chemotherapy combination.…

By. Kim Margolin, MDDate. 11/17/2023In the field of cancer immunotherapy, Kim Margolin, MD, provides insights into the interplay between the innate and adaptive immune systems. According to her, the innate immune system serves as a bridge, reacting swiftly against pathogens. This orchestration involves the secretion of cytokines, cytotoxic granules, and the engulfing of pathogens. Margolin emphasizes the concert between innate and adaptive immune responses, highlighting the significance of acute inflammation in anticancer reactions, in contrast to immunosuppression associated with chronic inflammation.Margolin delves into the field of tertiary lymphoid structures within tumors, elucidating their composition, which mirrors that of the adaptive…

By. Joaquim Bellmunt, MD, PhD Date. 11/17/2023 At the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, Dr. Joaquim Bellmunt, MD, PhD, from Harvard Medical School in Boston, MA, shared insights on advancements in renal cancer during a dedicated session. Discussing first-line treatment options, Dr. Bellmunt highlighted the four established choices, including combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors. In an interview, he touched upon the critical analysis of which patients are best suited for each treatment strategy. During the session, Dr. Bellmunt delved into the Phase III CONTACT-02 trial (NCT04446117) focusing on prostate…

By. Crispin Hiley, PhD Date. 11/17/2023 Crispin Hiley, PhD, from the UCL Cancer Institute in London, UK, discusses developments in second-line treatment for EGFR mutation-positive lung cancer patients at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain. Crispin Hiley, PhD, acknowledges progress in addressing the needs of patients who have progressed on osimertinib or third-generation tyrosine kinase inhibitors (TKIs). In an interview, Crispin Hiley, PhD, talks about studies on second-line EGFR mutation-positive lung cancer and the challenges faced by patients advancing on tyrosine kinase inhibitors. He acknowledges the existing unmet need, especially for those not suitable…

By. Mansoor Raza Mizra, MD Date. 11/16/2023 At ESMO this year, Mansoor Raza Mizra, MD, a figure in gynecologic oncology, shared insights on developments in the field. The focus began with cervical cancer, where three phase three randomized trials showed results. The Interlace trial, conducted in the neoadjuvant setting for locally advanced cervical cancer, demonstrated outcomes in both progression-free survival (PFS) and overall survival (OS). Another trial, exploring Cho radiation with or without pisab concomitant and maintenance in locally advanced cervical cancer, showed an increase in PFS, with a trend in OS, though data maturity is awaited. The third trial,…

By. Nicolas Girard, MD Date: 11/15/2023 In a significant development in the field of oncology, Nicolas Girard, MD, played a role in the approval of Amivantamab for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions. The approval specifically targets individuals who have experienced disease progression during or after platinum-based chemotherapy, representing an advancement in therapeutic options. The approval stems from a phase 3 international randomized trial overseen by Dr. Nicolas Girard and colleagues. In this trial, 308 patients with advanced NSCLC and EGFR exon 20 insertions, previously untreated with…

By: Allison Betof Warner, MD, PhD, StanfordDate: 11/13/2023 From: MOASCImmuno-Oncology Determining Optimal Treatment Duration Transcript: The question of how long to treat patients is one of the more challenging ones in our field. It’s always wonderful when our patients are responding. Classically in oncology, we kept patients on treatment indefinitely in the days of chemotherapy and even targeted therapy. Um, but we really feel that the immune system can learn to take care of a cancer itself from immunotherapy. And all of the data have suggested that over the years. the question is, how do we pick which patient is…

By. Aaron E. Lisberg, MD, Date. 11/14/2023 During ESMO 2023, Aaron E. Lisberg, MD, delivered a presentation on the results from the TROPION-Lung01 study, focusing on the clinical question of second-line chemotherapy for advanced metastatic non-small cell lung cancer compared to docetaxel. The study investigated a novel antibody-drug conjugate targeting TROPION-Lung01, Datopotamab deruxtecan, in a head-to-head comparison with docetaxel. Approximately 300 patients were enrolled and randomized at a one-to-one ratio, regardless of histology or the presence of targetable mutations. The trial had dual primary endpoints—progression-free survival (PFS) and overall survival (OS). Dr. Lisberg’s presentation concentrated on the PFS final analysis…

By. Filippo Pietrantonio, MD Date: 11/14/2023 Clinical data from the study demonstrated the inhibition of feedback reactivation pathways with an accumulation of activated GFR, providing a compelling rationale for combining Sotorasib with an anti-EGFR monoclonal antibody. Dr. Pietrantonio, MD, emphasized the need to enhance outcomes beyond monotherapy. The CodeBreak 300 trial, a global and phase 3 active-controlled open-label study, involved 160 patients randomized based on centrally confirmed KRAS G12C mutations after the failure of standard therapies. The trial featured three arms: Sotorasib at the standard dose (960 mg) plus panitumumab, Sotorasib at a lower dose (240 mg) plus panitumumab, and…

By. Peter Schmid, FRCP, MD, PhD Date. 10/11/2023 KEYNOTE-522 Phase 3 Results – Was Pembrolizumab a Win in Triple-Negative Breast Cancer? In this interview, Peter Schmid, FRCP, MD, PhD, from Barts Cancer Institute, London, UK, delves into the compelling 5-year follow-up data emanating from the Phase III KEYNOTE-522 (NCT03036488) trial. The trial was designed to investigate the efficacy of combining pembrolizumab with chemotherapy as neoadjuvant therapy and pembrolizumab as adjuvant therapy in patients grappling with the challenges of triple-negative breast cancer. The previously reported findings from the trial had already indicated noteworthy and statistically significant improvements in both pathological complete…

By. Funda Meric-Bernstam, MD Date. 10/11/2023 LBA34 – Trastuzumab deruxtecan (T-DXd) for pretreated patients with HER2-expressing solid tumors. Professor Funda Meric-Bernstam presented pivotal findings at the ESMO Congress 2023, shedding light on the latest developments in the realm of cancer treatment. The focal point of her presentation was the noteworthy LBA34 – Trastuzumab deruxtecan (T-DXd) for HER2-expressing solid tumors. These insights emanated from the primary analysis of the DESTINY-PanTumor02 (DP-02) study, offering a comprehensive examination of T-DXd’s efficacy in a diverse cohort of patients. The study, designed to address the therapeutic potential of T-DXd, specifically targeted patients with HER2 expression…